[{"article": "COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nThe various findings suggest that treating lung cancer - the biggest cancer killer globally - with powerful new immune system-boosting medicines is going to involve more permutations than some experts originally expected.\nIn the event, researchers reported that Merck\u2019s combination cut the risk of disease progression or death by 47 percent compared to chemotherapy alone after 10.6 months, while 55 percent of patients saw their tumors shrink versus 29 percent.\nMany now believe that combination therapy is the way ahead, with Bristol and AstraZeneca working primarily on using two immunotherapies together, while Roche and Merck look at adding chemotherapy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story just barely scores a Satisfactory rating on this one. It is clear that Merck & Co. is funding this research. A couple of sources are overtly linked to the company. A third, Dr. Stefan Zimmerman, appears to be independent, though he\u00a0wasn\u2019t quoted saying anything that helped illuminate the findings, instead he\u2019s quoted as saying \u201cRemember this day. It\u2019s a new day for lung cancer treatment.\u201d Some additional commentary from an oncologist or a patient advocate would likely have helped put the findings in perspective.", "answer": 1}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only non-peer-reviewed company-sponsored research was reported.\u00a0 No independent sources were cited. ", "answer": 0}, {"article": "It's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nThose parts of the brain soon start to die.\nA stroke occurs when a clot cuts off blood flow to parts of the brain.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted. But it would have been better if he\u2019d been quoted on the quality of the evidence.", "answer": 1}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\nWe don\u2019t have to pay for manufacturing.\u201d\n\nThe Wegman family \u2014 the two sons and the founder\u2019s 75-year-old wife, Toby \u2014 controls about 25 percent of the company\u2019s stock.\nWhile collagenase itself is not patented, the companies do have patents on the use of the enzyme to treat Dupuytren\u2019s and Peyronie\u2019s.\n\u201cIt was to me just like a miracle.\u201d\n\nXiaflex is an enzyme produced by a gangrene-causing bacterium, Clostridium histolyticum, which uses it to eat away the tissues of its victims.\nAnd there are times doctors need to break down collagen, such as when an excess builds up in the hand or penis, causing Dupuytren\u2019s and Peyronie\u2019s.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Most of the sources in this story are affiliated in some way with organizations that will profit from the sale of Xiaflex. These conflicts are disclosed, however, and the story does offer some clinical perspective from a hand specialist who does not appear to be connected to\u00a0Xiaflex. \u00a0", "answer": 1}, {"article": "Amid a growing body of evidence on the health impacts of the sport, the consensus aims to help current and would-be players maximise the health pros and minimise the health cons of golf, and to guide policy-makers and industry leaders on how best to make golf more inclusive and accessible and so encourage more people from all walks of life to take up the sport.\nEvidence suggests it may not only be good for mind and body, but also for a long life\n\nThe consensus--one of the first of its kind--comes on the eve of the Ryder Cup, the biennial golf tournament between Europe and the US.\nCompared with other sports, the risk of injury is moderate, but as it's an outdoor activity, golfers may be more at risk of skin cancer.\nIt can provide moderate intensity aerobic physical activity, and its health benefits are greatest for players (and spectators) who walk round the course rather than opt for a golf cart.\nAnd the sport can do its bit for sustainability by \"practices that prioritise diversity, healthy societies, connection with, and care of, the environment, environmental integrity and health and wellbeing,\" the statement suggests.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is the second major weakness of this news release.\nIt\u2019s not mentioned that this \u201c2018 Consensus Statement on Golf and Health\u201d was funded by an unrestricted grant from the World Golf Foundation.\nTwo of the authors receive fees from the European Golf tour and one is the director of Golf Development at the Royal and Ancient Golf Club in St. Andrews, Scotland.", "answer": 0}, {"article": "The patient blows a single breath into a specialized balloon.\nDr. Schumer said those grim statistics underscore the need for early detection, \u201cWe hope that breath analysis will allow us to diagnose patients with primary or recurrent lung cancer long before they suffer from symptoms, when we have more options for treating them, giving them the best chance for cure.\u201d\n\nCurrently, lung cancer patients are followed after surgery with chest computed tomography (CT) scans, which can be inconvenient, expensive, and expose the patient to radiation.\nBousamra, van Berkel, and Fu disclose a financial relationship with Breath Diagnostics, Inc.\n\nFor a copy of The Annals article, contact Jennifer Bagley at 312-202-5865 or jbagley@sts.org.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\nThe researchers found a significant decrease in overall carbonyl VOC levels following surgery; in fact, three of the four carbonyl VOCs normalized after surgery, matching levels in the control group.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release earns a satisfactory here for providing both funding sources and pointing out that three of the seven researchers have ties to a medical equipment company which deals with breath analysis. The information, however, lies at the end of the story in a portion commonly referred to as \u201cboilerplate\u201d information, which readers often ignore. Incorporating such info into the body of the release better serves readers.", "answer": 1}, {"article": "\u201cNo,\u201d Dr.\nBut it also sends a signal to the brain that says \u2018you\u2019ve eaten.\u2019 Fructose doesn\u2019t stimulate insulin secretion, and if there\u2019s no insulin, you don\u2019t get the information that you\u2019re full.\u201d\n\nDoes this mean that it is a good idea to avoid fruit, because it contains fructose?\nBefore having their drinks, the participants rated their desire to eat on a one-to-10 scale from \u201cnot at all\u201d to \u201cvery much.\u201d Then they drank the liquids and had functional magnetic resonance imaging brain scans while looking at images of food and of neutral objects like buildings or baskets.\nAnd it is packed with fiber, which helps slow down the absorption of food, which makes you feel full.\u201d\n\n\n\n For more fitness, food and wellness news, \u201clike\u201d our Facebook page.\nThe study, published in the journal PNAS, found that compared with glucose, consuming fructose produced greater responses to food cues in the orbital frontal cortex of the brain, a region that plays an important role in reward processing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites only one source, and clearly notes that the source is an author of the relevant study. However, the story lacked an independent expert to put the work in context.\u00a0This story badly needed that context to give us a sense of how important this work might be, and what similar work may have been done in this area. For example, maybe the cues for people to eat junk/high-calorie foods are so strongly triggered by other behavioral patterns that making substitutions of sugars in processed foods won\u2019t matter anyway.", "answer": 0}, {"article": "Nov. 28, 2011 (Chicago) -- Researchers are using high-energy waves similar to those used to make microwave popcorn to destroy inoperable lung tumors.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nU.S. researchers say the technique certainly shows promise.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent source: American Society of Clinical Oncology spokesman Gregory Masters, MD, a medical oncologist at the Helen F. Graham Cancer Center. More sources could have deepened our understanding of the technique.", "answer": 1}, {"article": "A University of Colorado Cancer Center study published today [May 3] in Oncotarget shows that combining a CPT1A inhibitors with anti-androgen therapy increases the cancer\u2019s sensitivity to the anti-androgen drug enzalutamide.\n\u201cThere is a critical need for improved therapies for this specific cancer type.\u201d\n\nMost cells use the energy of glucose (sugar).\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\nHowever, there are many steps involved in lipid metabolism and researchers have been working to break prostate cancer\u2019s ability to harness this energy source.\n\u201cWe had to find a way to block this pathway so that the cancer would not be able to burn lipid in the mitochondria to acquire energy to resist therapy,\u201d explains Schlaepfer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders aren\u2019t named in the news release. There is no information suggesting\u00a0that the researchers are connected to the companies that make the drugs in question or are otherwise invested in this particular treatment paradigm, but it would have been nice to be informed if this was or was not the case.", "answer": 0}, {"article": "Dr. Beth Karlan, director of gynecologic oncology at Cedars Sinai Medical Center in , said the results of the new trial would \u201cmake us all rethink the approach to treating patients with recurrent ovarian cancer.\u201d\n\nDr. Karlan, who was not involved in the study but presented a commentary on it, said CA125 testing should be done less frequently.\n\u201cI was in a constant state of , waiting for the test, waiting for the results,\u201d she said.\nDoctors are convinced that if the initial diagnosis can be made early, which is very difficult, the cancer can be treated by surgery.\n\u201cMany women often say they live from one CA125 to the next,\u201d she said.\n\u201cI\u2019ve had patients who wouldn\u2019t dream of not being treated,\u201d Dr. Berchuck said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several experts who are not involved in the story, providing valuable perspective on the results.", "answer": 1}, {"article": "\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\nThe study, which used rats in lieu of human children, found evidence that reward pathways are severely altered following exposure to drugs that affect the brain.\nThe Oxford paper notes that 3 percent of children ages 6-12 and nearly 6 percent of teenagers ages 13-18 suffered from major depressive disorder, the psychiatric term for what is colloquially known as depression.\nSince 2004, the FDA has advised that antidepressants not be prescribed to individuals under 24 due to the increased risk in suicidality, especially during the early phases of treatment.\nThat\u2019s because the FDA has deemed that Prozac has demonstrated benefits that outweigh one of the suspected downsides of antidepressants in kids and teens: disrupting brain development.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not mention that the study was funded by the Chinese government through the National Basic Research Program of China or that the researchers collectively have financial ties to numerous drug companies.", "answer": 0}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter sought out opinions from two clinicians not connected to the study, a patient, the Mayo Clinic, and the National Osteoporosis Foundation. But the story was not transparent about the relationships that these sources have with commercial interests. Dr. Amy Singer has disclosed significant financial ties to Amgen, which makes an osteoporosis drug. We\u2019d also note that the National Osteoporosis Foundation receives funding from a \u201cCorporate Advisory Roundtable\u201d that includes makers of bone scanning machines and osteoporosis drugs. And the Foundation has previously been called out for its failure to educate consumers about the harms of bisphosphonate drugs when those problems were first coming to light. This context should make us wary of a push to screen more men for osteoporosis without evidence that it is beneficial. Is this drive totally about the patient or could there be a commercial motivation?", "answer": 0}, {"article": "The number of prostate cancer diagnoses dropped by more than 12% (1363 cases) in the month after the USPSTF draft guideline was issued and the number continued to drop, resulting in an overall decline of 28% in incident prostate cancer diagnoses in the year after the draft guideline was issued.\nThe decreases were similar across all subgroups of age, comorbidity, race, income, and insurance.\nThey identified incident cancers diagnosed between January 2010 and December 2012 in the National Cancer Database and assessed the trend of new prostate cancers diagnosed each month before and after the draft guideline was issued, comparing their findings with colon cancer.\nWhile it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology\u00ae.\nSimilarly, new diagnoses had fallen by 23.0-29.3% among men over age 70 and by 26.0% among infirm men, populations at risk for harms of treatment but unlikely to live long enough to benefit from early detection.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not discuss funding for the study and does not disclose the fact that some authors have financial relationships with companies that make prostate cancer tests and treatments.", "answer": 0}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cNow, patients can undergo a minimally invasive procedure to fix complex problems of the aorta without having open surgery.\u201d\n\nThe Valiant Navion\u2122 thoracic stent graft system is delivered from a groin blood vessel into the aorta, is positioned above the affected aneurysm, and is deployed under x-ray guidance.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\n\u201cThis was a difficult surgery, but I knew I was in good hands,\u201d said Angelino, 85, of Culver City.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders of the study are not named (nor is the study that led to the device approval identified or linked). It is good to know that the surgeon featured in the news release, Dr. Azizzadeh, works \u201cin conjunction with medical device company Medtronic, [and] served as the national principal investigator in clinical tests of the device.\u201d", "answer": 0}, {"article": "Kerry Aldrich, 15, suffered a concussion playing varsity soccer for The Potomac School in McLean, Va., three weeks ago when she did a face-first dive and violent somersault.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\n\"The brain, in its development, while it is actively developing, seems to be less able to take these forces and to really rebound from these forces,\" Dr. Gioia observed.\n\"I wasn't worried,\" Aldrich says, \"until my doctor and my mom were, like, hinting that if this happens again I probably won't ever be able to play soccer again.\"\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe broadcast includes interviews with an independent expert who describes the potential problems posed by premature return to play. However, it fails to mention that the other expert interviewed, Michael Collins, PhD, is a part owner in the company that developed and licenses the Impact system.\n", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cThese encouraging results support the development of a large, randomized trial to directly compare HDIT/HCT to standard of care for this often-debilitating disease.\u201d\n\nMS symptoms vary widely and may include motor and speech difficulties, weakness, fatigue and chronic pain.\nThe researchers published three-year results from the study in December 2014, and the final five-year results appear online Feb. 1 in Neurology, the medical journal of the American Academy of Neurology.\nThe trial, called HALT-MS, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN).\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the research was sponsored by the National Institute of Allergy and Infections Diseases and the NIH. But it does not mention that Baxter Healthcare Corp. supplied equipment for the trial or that several study authors have financial relationships with biotechnology companies, which are listed in the study.\nIt\u2019s not easy to determine which companies have financial interests in hematopoietic stem cell transplantation, but Baxter has at least one patent relating to the procedure. This makes full disclosure an important aspect of the reporting of this trial. ", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A few different independent experts raise concerns about the quality of the evidence supporting these products, their effectiveness, and their potential to cause harm. And the story seems to identify relevant commercial relationships that represent a conflict of interest. This was the major strength of the story; but\u00a0as noted above, we think these sources could have been put to better use.", "answer": 1}, {"article": "It took a year for the company to get clearance for the trial from the F.D.A.\nMeanwhile, Advanced Cell Technology, of Marlborough, Mass., said it would test its stem cell therapy on 12 adults with severe vision loss caused by Stargardt\u2019s, an inherited disease.\nRegeneron\u2019s drug, which is called VEGF Trap-Eye, \u201cgives us the opportunity to not have to see them monthly,\u201d said Dr. Jeffrey Heier of Boston, an investigator in one of the trials and a consultant to Regeneron.\nAlso, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\nHuman embryonic stem cells are controversial because their creation usually entails the destruction of human embryos, although Advanced Cell Technology is working on a technique to avoid that.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert source quoted in the story was an investigator on the study of the new drug. Although the story disclosed that he was a consultant for the drug\u2019s manufacturer, Regeneron,\u00a0it should have sought out a comment on the findings from\u00a0somebody with no stake in the research. This is especially important considering the findings were not published in a journal and presumably have not been vetted by other researchers.", "answer": 0}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No one truly independent of the Medtronic-Lilly partnership was quoted.\u00a0 We would have liked to have seen independent expert perspective on the approach.", "answer": 0}, {"article": "\u201cBut this is a small study, a proof of concept.\n\u201cWe can\u2019t yet say that this study means that DHEA is a viable alternative to HRT, but ... we should be looking to do larger studies to confirm these initial results.\u201d\n\nDHEA, or dehydroepiandrosterone, is a natural steroid hormone mostly made in the adrenal glands and has a variety of therapeutic uses.\nAmerican researchers said in January that the antidepressant Lexapro, made by drugmaker Forest Laboratories, significantly cut the number and severity of hot flushes in menopausal women, and other antidepressants including GlaxoSmithKline\u2019s Paxil and the Pfizer drugs Prozac and Effexor also have been found to be effective.\nItalian researchers writing in the journal of the International Menopause Society, Climacteric, said they had found the first robust evidence that low doses of DHEA can help sexual function and menopausal symptoms, suggesting it may one day become an alternative to hormone replacement therapy (HRT).\nAt the start of the trial, all groups had similar sexual activity, but after the year, those taking calcium and vitamin D scored an average of 34.9 on the questionnaire scale, while those taking DHEA had a score of 48.6, showing that those on DHEA had more sexual interest and activity.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does not quote any outside sources, which we know can be driven by deadline demands. The bigger problem with the story, and it\u2019s a problem shared by many stories about hormone treatments, is that it does not acknowledge the authors\u2019 conflicts of interest. Dr. Andrea Genazzini, for example, has worked with pharmaceutical companies on multiple articles that were ghostwritten by the companies\u2019 marketing firms. You can find this by looking in the Drug Industry Document Archive. We know that it\u2019s tough to cover all the bases when juggling multiple stories in a day, but we hope that more reporters will take the time to at least do a name check on researchers involved in studies of hormone therapy, antidepressants and other drugs that have been the subject of lawsuits and federal investigations. There is a wealth of information in the archive, and readers deserve to know more about it.\n\u00a0", "answer": 0}, {"article": "THURSDAY, July 20, 2017 (HealthDay News) -- A laser treatment can reduce spots in people's vision known as \"floaters,\" a new study finds.\n\"Floaters often arise as the vitreous -- a gel-like substance that fills the eye -- contracts and pulls away from the back of the eye,\" explained ophthalmologist Dr. Naomi Goldberg, who reviewed the new research.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\n\"Greater confidence in these outcomes may result from larger confirmatory studies of longer duration,\" the study authors wrote.\nThey explained that, currently, there are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote an independent source in the story, rather than relying on the study\u2019s authors.\u00a0 It does not, however, provide any information relating to possible conflicts of interest. For example, the study was funded by a large ophthalmology clinic where this procedure is presumably performed \u2014 and which might stand to gain more business if it\u2019s proven to work effectively.", "answer": 0}, {"article": "The findings are mixed on substance abuse.\n\u201cIt\u2019s a shift from having our mental health defined by the content of our thoughts,\u201d Dr. Hayes said, \u201cto having it defined by our relationship to that content \u2014 and changing that relationship by sitting with, noticing and becoming disentangled from our definition of ourselves.\u201d\n\nFor all these hopeful signs, the science behind mindfulness is in its infancy.\nA recent review by Canadian researchers, focusing specifically on mindfulness meditation, concluded that it did \u201cnot have a reliable effect on depression and anxiety.\u201d\n\nTherapists who incorporate mindfulness practices do not agree when the meditation is most useful, either.\n\u201cWith the really hard stuff, you need something else, something that allows people to tolerate these very strong emotions.\u201d\n\nIn the 1990s, Dr. Linehan published a series of studies finding that a therapy that incorporated Zen Buddhist mindfulness, \u201cradical acceptance,\u201d practiced by therapist and patient significantly cut the risk of hospitalization and suicide attempts in the high-risk patients.\nWith Dr. Kabat-Zinn, they wrote a popular book, \u201cThe Mindful Way Through Depression.\u201d Psychotherapists\u2019 curiosity about mindfulness, once tentative, turned into \u201cthis feeding frenzy, of sorts, that we have going on now,\u201d Dr. Kabat-Zinn said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an excellent job balancing comments from several leading proponents of mindfulness therapies with summaries of the evidence of this practice in clinical trials. The story discusses caveats that the practice may be useful as part of an integrative treatment plan; however, evidence suggests it is not a panacea for depression or anxiety, and it should be used with caution (or not at all) with some patients.\u00a0 The journalist should be commended for the range of mindfulness experts, clinicians and patients interviewed in the article. This is a well-balanced report providing the reader with good information on a trend in medicine, but appropriately tempering over-enthusiam for the practice with available evidence.\u00a0 ", "answer": 1}, {"article": "(Reuters) - Tiny Israeli drugmaker Oramed Pharmaceuticals Inc on Wednesday said its experimental oral insulin succeeded in significantly reducing night-time blood glucose in patients with type 2 diabetes, according to initial data from a midstage trial.\nThe result is likely to surprise many skeptics who did not believe insulin could be delivered orally because they doubted it could survive the onslaught of digestive juices so it could have the intended effect.\n\u201cIt\u2019s been a long trip but it\u2019s finally at the point that it\u2019s beyond a doubt, the oral insulin works,\u201d Nadav Kidron, chief executive of Jerusalem-based Oramed, said in a telephone interview.\nThe main attraction of an insulin pill, aside from avoiding injections, is that it comes much closer to the path of natural insulin, which is produced in the pancreas and goes directly to the liver.\nWhile insulin is typically associated with type 1 diabetes, many patients with type 2 eventually see their disease progress to the point where they need insulin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from the CEO.\u00a0Getting an independent voice is especially important when the data is preliminary and comes from the pharmaceutical company.", "answer": 0}, {"article": "SAN DIEGO, CA - Knee pain in active patients over 40 is often difficult to treat but according to researchers presenting their work today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Annual Meeting in San Diego utilizing a special kind of allograft may be a step in the right direction.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\nThe study group consisted of 38 patients, 10 women and 28 men who were at least 40 years of age and a control group with 42 patients (27 men and 15 women) who were 39 years of age or younger.\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not say how the research was funded, nor does it address conflicts of interest. To be clear, the research may have been internally funded, and there may well be no conflicts of interest \u2014 but it\u2019s important for a release to state that explicitly.", "answer": 0}, {"article": "WATCH: The naked mole rat might help us cure cancer\nThe research, led by Richard Wilson of Harvard University, revealed that in more than 500 US counties, mammography screening programs were linked with more diagnoses of smaller breast cancers \u2014 but not with fewer deaths or with fewer larger breast cancers (which theoretically would be prevented by finding the disease early through screening).\nIn a related commentary in the journal, a pair of doctors from the University of Washington School of Medicine note that the estimates of overdiagnosis of breast cancer are \"frustratingly broad\" \u2014 from less than 10 percent to 50 percent or more of women who get screened.\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis.\nThe US Preventive Services Task Force, which analyzes the best available evidence to create guidelines for doctors, now recommends biennial mammography screening for the general population in women ages 50 to 74.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites independent commentary from an accompanying editorial that provides useful context. Inclusion of a second independent voice might have drawn attention to some of the study\u2019s limitations as discussed above. The story doesn\u2019t discuss potential conflicts of interest among the study authors, but the only conflict disclosed with the manuscript was related to a company that makes thermometers. Overall, this seems Satisfactory to us.", "answer": 1}, {"article": "All were enrolled in the CHARGE study (CHildhood Autism Risks from Genetics and Environment) from 2003 to 2009.\nThe mothers with the high-risk form of MTHFR had a 4.5 times higher chance of a child developing autism, she says, than mothers without this high-risk form who did take the prenatal vitamins.\nIt may be that the vitamins contribute to high levels of folate.\nThe risk rose if the mothers or the children had a high-risk gene form.\nThe research needs to be duplicated, Hertz-Picciotto tells WebMD.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert who was not involved with the research and who is identified as working for an advocacy group. There don\u2019t seem to be any other potential conflicts to disclose.", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several independent experts who have differing views on the value of the new information. It did an especially good job of noting conflicts of interest where they existed. ", "answer": 1}, {"article": "\"It's meaningless, and it could very easily introduce real confusion.\"\n\"There is concern about the validity of many genetic tests that are being offered,\" said Joan Scott, deputy director of the Center for Genetics and Public Policy at Johns Hopkins University.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\n\"There is at least a significant chance this test will could falsely reassure some women and alarm others,\" said Eric Winer, a breast cancer expert at Harvard Medical School and a spokesman for the American Society of Clinical Oncology.\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several leading breast cancer researchers, a member of the American Cancer Society and a spokesperson for the FDA are interviewed for this story. These interviewees do not have a vested interest in this test\u2013unlike Decode\u2019s chief executive, who is also interviewed, mainly promoting his company\u2019s product.\u00a0 Researchers help educate the reader about a new test may have many more cons than pros.\u00a0 The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts.", "answer": 1}, {"article": "The study was presented Monday at the annual meeting of the American Society of Hematology in Atlanta.\n\"As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but we did not know if physical activity would have an impact on survival in lymphoma patients,\" said study author Dr. Priyanka Pophali, a hematologist at Mayo Clinic.\nOn the other hand, people whose physical activity level had declined after their diagnosis had higher death rates from lymphoma and other causes than those who had not changed their level of physical activity.\n\"Therefore, since physical activity behaviors can be modified, physicians should counsel patients and survivors on the importance of physical activity and encourage them to maintain and, if possible, increase their level of physical activity.\"\n\"Our findings show that physical activity can have a positive impact on survival in lymphoma patients,\" she said in a Mayo news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are cited in the story, nor does the story tell readers who funded the relevant study or whether there are any potential conflicts of interest among the researchers. (The study abstract itself doesn\u2019t tell readers who funded the study, though it does list the various industry relationships of the researchers.)", "answer": 0}, {"article": "Line Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\nSo the researchers use infrared light, delivered by an extremely fast-pulse laser.\nCataracts are the leading cause of blindness in the world, and are often related to aging.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted. ", "answer": 0}, {"article": "Anderson and a co-author of the study.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\nThe pancreas is located deep within the body, so early tumors cannot be seen or felt during routine physical exams.\nPancreatic cancer has one of the lowest survival rates of any cancer, with only 4 percent of patients surviving five years after diagnosis.\nAs a result, 80 percent of pancreatic cancer is diagnosed in later stages, when surgery is no longer an option.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert quoted in the story is a coauthor of the study. We think it\u2019s always prudent to consult an independent third party to vet claims. In addition, while the story includes some background on the prevalence and outcomes of pancreatic cancer, these reviewers were disappointed to see that these statistics were not sourced. There are a couple reasons why attributing sources of claims and statistics is important. Obviously, readers may want to do additional reading and providing a source points them in the right direction. Another reason it\u2019s important to provide attribution is that statistics have been known to vary among advocacy groups, medical associations, companies, foundations and government institutions. It\u2019s not unheard of for groups pushing for more awareness and funding to select a higher number \u2013 among those available \u2013 to further their cause.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did mention where the research was conducted and the journal in which it was published.\u00a0 However, it did not contain any obvious input from experts in the field.", "answer": 0}, {"article": "The pill is his blood pressure medication.\n\"If you had a stroke, even a small stroke, your risk of dementia within the next two years was greatly magnified,\" he says.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nIf people knew about the link between dementia and high blood pressure, they might be more inclined to do something about it, Koroshetz says.\nAnd when the heart pushes too hard, as it does when blood pressure is elevated, it can cause damage that can lead to a stroke.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an official of the Alzheimer\u2019s Association, which has an obvious interest in the prevention and treatment of AD. But NPR would have added much credibility to the story with some cautionary note from outside sources about the nature of the evidence for blood pressure control and AD prevention.", "answer": 0}, {"article": "\u201cWhen drugs don\u2019t work, what else is there?\u201d\n\u201cIt quickly becomes clear that \u2018weird\u2019 is going to be just fine if it replaces the pain.\u201d\n\nChronic pain is a particularly difficult problem to understand and solve.\n\u201cSometimes efficacy wanes over time, but I still believe in them,\u201d said Dr. Kaufman, also an assistant professor of anesthesiology at the New Jersey Medical School.\nThe study, which was financed by the implant maker Medtronic, followed 100 patients who had undergone spinal surgery and had developed chronic pain in one or both legs.\nStill, most patients accept this vibrating version of white noise, says Dr. Richard North, a retired neurosurgery professor at Johns Hopkins who developed several patents related to the technology, although he no longer receives royalties.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides a good mix of sources, including one patient and three pain experts (one of whom relates the story of a dissatisfied patient). It also reports a potential conflict of interest among the authors of the study it cites, as well as with one of the expert sources.", "answer": 1}, {"article": "But a spokesman for the company that manufactures Lap-Band says the study is flawed.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nHe emphasizes he is not against the use of gastric band surgery, but that based on his study results, patients who opt for the procedure should know there's a good chance they will need a follow-up procedure and they may have less weight loss and more complications than those who choose other weight loss surgeries.\nDespite that degree of satisfaction, \"I think people have exaggerated expectations from the band procedure,\" says researcher Jacques Himpens, MD, an attending surgeon at St. Pierre University Hospital in Brussels.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interview comments from a company spokesperson and one of the authors of the study, both of whom were clearly identified. \u00a0The story also included this important detail about the quoted author, which was missed by the HealthDay story we reviewed. \u201cHimpens reports consultant work for Ethicon Endosurgery, which makes another gastric band, Realize, and for Covidien, a health care products company.\u201d In addition, the story had comments from two surgeons who do not appear to have direct ties with either the manufacturer of the product or the study reported on. We were a little concerned about some of the phrasing in the story. It says, \u201cBut some, including the manufacturer of the Lap-Band \u2014 used in a technique called laparoscopic adjustable gastric banding \u2014 take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.The critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\u201d This leads readers to believe that there are mulitple critics out there pointing out flaws in the study. The story itself, though, only quotes one actual critic: the company spokewoman. The criticisms may be valid, but readers deserved a strong independent analysis of the study\u2019s limitations.", "answer": 1}, {"article": "GALVESTON, Texas -Researchers from The University of Texas Medical Branch at Galveston found that testosterone replacement therapy may slow disease progression of chronic obstructive pulmonary disease.\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\nSpecifically, middle-aged testosterone replacement therapy users had a 4.2 percent greater decrease in respiratory hospitalizations compared with non-users and older testosterone replacement therapy users had a 9.1 percent greater decrease in respiratory hospitalizations compared with non-users,\" said Baillargeon.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders of the study are not named in the release. The lead author, we learn in the full paper, \u201chas received payment, for consulting, from AbbVie, Endo Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, and Auxilium Pharmaceuticals.\u201d\u00a0Some of these companies manufacture testosterone replacement therapy.\u00a0 This was not mentioned in the news release.", "answer": 0}, {"article": "(March 23, 2017)\u2014Statin drugs are widely used to manage high cholesterol and reduce the risk of cardiovascular disease.\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nNOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209.\nThe Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.\nIn some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Since this was based on a review article we don\u2019t require a named funding source to rate this satisfactory. Nor do we have any evidence that the authors have any conflicts of interest. If there was, we would expect the news release to include them. ", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Multiple sources are quoted.", "answer": 1}, {"article": "See the Cartoons of the Week.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nThe question of how soon children should be screened for high cholesterol is becoming increasingly important in the U.S., with its rate of child obesity topping 20%.\nBut because West Virginia has one of the nation's highest rates of death from heart disease, since 2000, the state has offered free, universal cholesterol screening to all fifth-graders enrolled in public schools.\nIn the new study, led by Dr. William Neal of West Virginia University, scientists observed a group of more than 20,000 fifth-graders in West Virginia and found that 71% were eligible for cholesterol screening based on national criteria.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe journal Pediatrics stated that the study authors did not have any relevant financial interests. The story does include comments from an independent expert; however, the independent expert addresses only questions about the efficiency of screening, not the health benefits or harms of identifying children with elevated cholesterol.", "answer": 1}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As already noted, the quote from the California geriatric neurologist was crucial.\u00a0 But other independent experts were quoted as well.\u00a0 Excellent sourcing.", "answer": 1}, {"article": "And we were thrilled to see such a huge impact.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\nBut the National Institutes of Health is under budget pressure, and the other major source of money for medical research, the pharmaceutical industry, has little incentive to study palliative care.\nAlthough the study could not determine why the patients lived longer, the authors and other experts had several theories: depression is known to shorten life, and patients whose pain is treated often sleep better, eat better and talk more with relatives.\n\u201cThe billing is complicated, and for many physicians that\u2019s enough of a deterrent to not bother.\u201d\n\nDr. Cooney herself had such care along with surgery and chemotherapy for ovarian cancer in 2008.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A strong effort here. The story quotes one of the study authors,\u00a0an independent\u00a0editorialist, a physician-writer knowledgeable\u00a0about end-of-life\u00a0care,\u00a0as well as leaders of professional groups that support hospice and palliative care.\u00a0", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes some good contextual comments from\u00a0Dr. James Aisenberg, a gastroenterologist and clinical professor of medicine at Mount Sinai Medical Center in New York. It also points out that there is a financial upside for the lead researcher in the study and the company that helped fund it: \u201cDr. Zalis and some of his co-investigators developed the software. The American Cancer Society, the National Institutes of Health and General Electric Co.\u2019s health-care unit\u2014which markets scanning devices and accessories\u2014supported the researchers. Dr. Zalis says the company had no influence on the study.\u201d", "answer": 1}, {"article": "\"It's kind of an extreme makeover of a cell,\" said Douglas A. Melton, co-director of the Harvard Stem Cell Institute, who led the research.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\nThe experiments, detailed online yesterday in the journal Nature, raise the prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.\n\"I see no moral problem in this basic technique,\" said Richard Doerflinger of the U.S. Conference of Catholic Bishops, a leading opponent of embryonic stems cell research.\n\"It's an important proof of concept,\" said Lawrence Goldstein, a stem cell researcher at the University of California at San Diego.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did include interview material from individuals not directly connected with the study reported on. And the story did include a comment from a stem cell researcher indicating that it is likely not a quick, straight shot from these results to use in people. The other sources interviewed provided a modicum of balance. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The writer notes her prior position as director of NIH, and cites the chief of the Women's Health Initiative branch of NIH. ", "answer": 1}, {"article": "What's more, he added, there are already several good ways to catch colon cancer -- or, even better, precancerous growths called polyps, which can then be removed before a tumor develops.\nIt's still unclear which breath chemicals should be measured, or what statistical method is best for weeding out cases of colon cancer.\nIn the end, the researchers were able to correctly identify the cancer patients 76 percent of the time.\n\"Colon cancer is a highly preventable disease,\" Brooks said.\nThey then used a statistical model to see if certain VOC patterns separated the colon cancer patients from the healthy participants.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An expert from the American Cancer Society\u00a0provides much-needed context and perspective on this research.", "answer": 1}, {"article": "This post has been updated.\nDespite the decades of marketing of mammography to women, \"women are capable of understanding the complexities of the issue, evaluating the evidence and making their own health decisions,\" she said in a statement.\nFran Visco, president of the National Breast Cancer Coalition, said the task force's guidelines for women in their 40s \u2014 that they should discuss whether to get mammograms with their doctors and make individual decisions \u2014 come closest to following the evidence accumulated over the past three decades.\nAs a result of the congressional action, women in their 40s will continue to be able to get annual mammograms at no cost.\n\"At this time, what does concern us very much are attempts by Congress to interfere with the makeup and process of the US Preventive Services Task Force.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from several independent sources. Comments from Fran Visco of the National Breast Cancer Coalition are worth repeating: \u201cWomen are capable of understanding the complexities of the issue, evaluating the evidence and making their own health decisions.\u201d", "answer": 1}, {"article": "Data suggest that the drug begins to affect sexual satisfaction after four weeks of continuous treatment.\nBut the difference was important to the women, says study researcher Michael L. Krychman, MD, medical director of sexual medicine at Hoag Hospital in Newport Beach, Calif.\n\n\"The absolute number of women who had remission of sexual distress was clinically significant, but equally important to them was how it improved their lives,\" Krychman tells WebMD.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\nWhile HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Conflicts of interest are disclosed.\u00a0 The story noted that the study researcher\u00a0interviewed is a paid consultant for the drug manufacturer.\u00a0 An alternative point of view is provided by\u00a0two independent experts, a\u00a0psychologist and a sex-therapist.\u00a0 The independent sources comment on the role that personal relationships play in sexual desire and experience which was not addressed or acknowledged by the researchers.\u00a0 ", "answer": 1}, {"article": "The scans measure brain activity by tracking the uptake of a radioactive liquid injected into the blood.\n\"Although the sample sizes and test sets were relatively small, the results are so promising that a much larger study would be worthwhile.\"\nBritish AI expert Prof Noel Sharkey, from the University of Sheffield, said of the findings: \"This is exactly the sort of task that deep learning is cut out for - finding high-level patterns in data.\n\"This study highlights the potential of machine learning to assist with the early detection of diseases like Alzheimer's, but the findings will need to be confirmed in much larger groups of people before we can properly assess the power of this approach.\"\nAs a final test, it was given a set of 40 scans from 40 patients it had never studied before.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes that were collected by the Science Media Centre, yet this wasn\u2019t disclosed. The other quote was from the news release, which also wasn\u2019t attributed.", "answer": 0}, {"article": "MONDAY, July 11, 2011 (HealthDay News) -- Teens who have high levels of folic acid appear to do better in school than those with lower levels, Swedish researchers report.\nFolic acid is one of the B vitamins and is a key component in making DNA and RNA.\nIt's not going to do us any harm and it might do us some good,\" he said.\nIn fact, folate deficiencies may be involved in the development of autism, he added.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from a clinician without apparent ties to the story were included in this story.", "answer": 1}, {"article": "The other half went to Weight Watchers meetings, had access to Weight Watchers' online materials and had two phone consultations and follow-up email contact with certified diabetes educators who told them how to modify the Weight Watchers plan to help with their diabetes.\nThe study's 563 participants were all overweight or obese and under a doctor's care for uncontrolled Type 2 diabetes.\n\"You can lose some weight and lower your blood sugar - and may even be able to change your medications.\nAfter a year, people in the Weight Watchers group had an average weight loss of about 4 percent of their starting weight, compared to 2 percent for the standard care group.\n\"The Weight Watchers people were significantly better off than people who received standard care.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes clear that Weight Watchers funded the study but does not disclose the lead investigators other financial ties to Weight Watchers. The published study states that several of the authors were Weight Watchers employees, held stock in the company, served on its board or were Weight Watchers product patent holders.", "answer": 0}, {"article": "\"Might this be a good application to help that person recover or prevent this decay from advancing?\n\"An alternative could simply be brushing better in a certain location and not drinking Coca-Cola all day long,\" says Mark Wolff, a professor of dentistry at New York University who specializes in cariology, or the study of tooth decay.\nHowever, some dentists argue that any time before a cavity actually forms, tooth decay can be stopped -- and even reversed -- by the patients themselves, using, for example, fluoride toothpaste.\nBut the third is a decay that is not so advanced, and Dr. Jin-Ho Phark, her dentist, is going to use a treatment he's testing that involves no drilling -- \"which is nice because many patients don't like the sound of the drill, and the feeling or the pain that might be associated with it,\" Phark says.\n\"When you take a sugar cube and you put it into your coffee, you will see that it is soaked up with the coffee,\" Paris says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n \nAlthough this story includes comments from an independent source and it identifies the lead researcher as being on of the product\u2019s developers\u2026 it fails to point out that the dentist featured in the story also has received financial support from product\u2019s manufacturer.\nReference: http://www.compendiumlive.com/print.php?id=3103", "answer": 0}, {"article": "Self-rated overall health [6] emerged as the single most powerful predictor of death in men, and previous cancer diagnosis the strongest predictor in women (see figure 1 of the Article).\n\"This is the first study of its kind which is based on a very large study sample, and is not limited to specific populations, single types of risk, or requiring laboratory testing.\"\nWhether this will help individuals improve self-awareness of their health status, however, or only lead to so-called cyberchondria, is a moot point.\nFor example, the research shows that self-reported information, such as usual walking pace and illness and injuries in the past 2 years, is generally a stronger predictor of death and survival than biological measurements, such as pulse rate and blood pressure.\nOf course, the score has a degree of uncertainty and shouldn't be seen as a deterministic prediction.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are clearly identified in the notes at the bottom of the press release.\u00a0 The investigators assert the absence of conflicts of interest in the journal article itself.", "answer": 1}, {"article": "\u201cThis is a patient population that\u2019s at risk for thrombotic [clotting] issues.\u201d\n\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nWe think the drug must at least diminish the food-seeking drive, which correlates to an increased caloric intake in patients.\u201d\n\nZafgen, founded in 2005, is backed by investors that include venture capital firms Atlas Venture of Cambridge and Third Rock Ventures of Boston.\nOur intention is to provide a plan for moving forward with an emphasis on patient safety.\u201d\n\nThe clinical results did not address a key issue for patients and regulators: whether Beloranib triggered the blood clotting that resulted in two patient deaths last year.\n\u201cThe efficacy of Beloranib looks very promising,\u201d said Dr. Merlin G. Butler, director of research and genetics at the University of Kansas Medical Center in Kansas City, Kan., and a principal investigator for the clinical trial there.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two sources appeared to have been interviewed for this piece, Dr. Hughes and Dr. Butler. The former is the chief executive of Zafgen while the latter is a medical researcher serving as a principal investigator of the clinical trial at the University of Kansas Medical Center. To meet our standard here, the story would have had to interview a source completely independent of the company and the trial. We rate this Not Satisfactory, but at least the article makes it clear that the studies under consideration are for a commercial drug.", "answer": 0}, {"article": "Utilizing IceCure Medical's innovative IceSense3\u2122 cryoablation system, the multi-center trial is examining cryoablation of certain types of breast cancer.\nPotentially, it will usher in a new and gentler pathway for the treatment of a disease that affects one in every eight women annually.\nPatents will be followed for five years to ensure they remain cancer free.\nCryoablation, however, precisely targets the tumor site and involves insertion of only a slim probe.\nA nick of the skin, a flash of cold and 25 minutes on an exam table.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "IceCure Medical, the manufacturer of ICE3, is named as the source of the\u00a0release.", "answer": 1}, {"article": "For more information, visit http://www.\nThe study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world.\nIn 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\n\"We've now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages,\" says Prof. Zeiri.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not give us information on funding or conflicts of interest. The full journal article states there are no conflicts.", "answer": 0}, {"article": "Fleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nThe FDA is apparently satisfied that 17-HP is safe, but it's requiring its sponsors KV Pharmaceuticals and TherRx to conduct further studies of women who have taken it and children exposed during pregnancy.\nThat's why it's a pretty big deal that the Food and Drug Administration has OK'd a drug, called 17-HP, that experts say could make a dent in the preemie problem.\nThe March of Dimes calculates that if all the women eligible to get the newly approved drug actually did, there would be 10,000 fewer preemies a year \u2013 out of more than half-a-million born that way.\nThe biggest reason why the United States has higher infant mortality than other developed countries is that American women are more likely to deliver prematurely \u2013 before 37 weeks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The medical director of The March of Dimes was quoted throughout. (Although they are seen as having a very pro-progesterone slant that is not held by consumer/advocacy/health policy/maternity care groups in UK, Australia, and Canada. in those countries surveys of providers uniformly get low utilization responses with the reason stated being need for more data. Similar surveys of US providers (specialty and generalists) show the vast majority use >70% (as opposed to low double digits in more evidence-driven countries) and that mission creep has started. Indications for which it is not tested see regular use in the US.)", "answer": 1}, {"article": "heart assocIation Mouth-to-mouth not necessary and seen as deterrent\n\nIn a break from decades-old first aid guidelines, the American Heart Association on Monday endorsed \"hands only\" cardio-pulmonary resuscitation - rapid chest compression without mouth-to-mouth resuscitation - to improve the odds for victims of cardiac arrest.\nThe latest revision stems from three major studies published last year that showed no advantage in using mouth-to-mouth resuscitation in cardiac cases.\nThese new guidelines are aimed at untrained bystanders, or to those who have been trained in CPR but are unsure they can perform it adequately.\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nAlthough survival rates for cardiac arrest hover around 10 percent with CPR, Hazinski noted that rates have been pushed as high as 30 percent in cities, such as Seattle, that combine high bystander participation with a strong system of professional emergency medical response.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites three sources, two of them associated with the American Heart Association (which developed the new guidelines) and one an apparently independent expert who supports the guidelines. ", "answer": 1}, {"article": "Breast Cancer Patients Have Improved Immune And Neuroendocrine Functions Following Massage Therapy.\nThe immune changes included increased white blood cells knowns as natural killer (NK) cells, which provide rapid responses to viral-infected cells.ii\n\nAn additional randomized study found women with stage 1 and 2 breast cancer may benefit from massage therapy for enhancing dopamine and serotonin while also increasing NK cell number and lymphocytes.\nAccording to research from Cedars-Sinai, participants in a Swedish massage group experienced significant changes in lymphocytes, which play a large role in defending the body from disease.i A lymphocyte is one of the three subtypes of white blood cells in the immune system.\n\"Researchers working with patients with compromised immune systems have found massage therapy can improve how the immune system functions,\" said Jeff Smoot, President of the American Massage Therapy Association (AMTA).\nThe American Massage Therapy Association, the most respected name in massage therapy, is the largest non-profit, professional association serving massage therapists, massage students and massage schools.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release doesn\u2019t list who the funders were for each study and whether there were any conflicts of interest.\nThe release is clearly identified as coming from a professional association and it\u2019s evident its purpose is to drive new customers toward association members.", "answer": 0}, {"article": "Is a drug really needed for what seems like a trivial use?\nThose patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\nObservers measured the symmetry of their smiles, checked for drool and listened to them read sentences.\n\u201cWe aren\u2019t reversing the local anesthesia,\u201d said Dr. Paul A. Moore, chairman of anesthesiology at the University of Pittsburgh School of Dental Medicine, who is an adviser to Novalar.\nWith about 300 million anesthesia injections given by dentists each year, company executives say the drug could easily achieve sales of hundreds of millions of dollars a year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed only company executives and dentists who consult with the company. No independent medical sources were consulted.\u00a0 \nGiven the questionable premise of the product, this is a remarkable omission. ", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has only one expert quoted, and that expert is an author of the study. Someone independent of the study would be in a better position to evaluate the claims objectively.", "answer": 0}, {"article": "Loading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\nThe authors of the new study wanted to look at what changes in diet do to one particular gut microbe species: a strain that\u2019s been associated with leanness and better glucose tolerance in mice.\n\u201cAll of the vegetables we\u2019re encouraged to eat by our mothers and by the government guidelines, these are all filled with fiber, and filled with a diversity of fiber, and probably the best route for encouraging a diverse microbiota,\u201d Sonnenburg says.\n\u201cWe discovered that the patients who exhibited higher amounts of were the patients who had a very strong improvement in cholesterol, in glycemia, in waist to hip ratio and also a reduction in different parameters in both cardiovascular disease and risk factors.\u201d\n\nHigher levels of , the findings suggest, seem to have favorable effects on health.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes one source who was not affiliated with the relevant study, but makes clear that the source is a vocal proponent of the idea that a high-fiber diet is important for maintaining a \u201chealthy\u201d gut microbiome and that the microbiome can have a significant impact on health.", "answer": 1}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included no quotes from the researchers or outside sources\u2013both could have provided important context and caveats about this kind of early-stage animal research, and the emerging results of this chemical, which also made recent headlines in cancer research, making us curious about why this study, now.\nAs for conflicts of interest, the article didn\u2019t mention any, and because the study coauthors declare none, we will assume that to be the case.", "answer": 0}, {"article": "It was surprising to see only 29 percent of patients received the recommended combination therapies, and as many as 20 percent are not getting any treatment six months after their diagnosis,\" said Dr. Lu-Yao.\nThe study was funded by the New Jersey Health Foundation, the National Cancer Institute (P30 CA-072720 and CA-116399 and the Rutgers Cancer Institute of New Jersey Biometrics Shared Resource.\n\"Our study suggests that removing the prostate followed by adjuvant radiotherapy is associated with greater overall survival in men with prostate cancer.\"\n\"Our data is revealing the real-world practice as well as some of the advantages and disadvantages of those medical preferences.\"\n\"One of the strengths of retrospective studies of patient data is that it reveals what happens in the real world, rather than the carefully controlled context of a clinical trial,\" said Dr. Lu-Yao.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release stated that the study was funded by the New Jersey Health Foundation, the National Cancer Institute, and the Rutgers Cancer Institute of New Jersey Biometrics Shared Resource.", "answer": 1}, {"article": "Newby and his team assessed how CTCA affected symptoms and quality of life six weeks and six months after the scan for 4,146 patients with suspected angina due to coronary heart disease.\n\u201cCertainly, this is something we now discuss in more detail with our patients, some of whom have declined CTCA.\u201d\n\n\u201cIt was striking for me that health status was very much related to receiving a (treatable) diagnosis or excluding such a diagnosis, rather than experiencing angina symptoms per se,\u201d said Dr. Paula M. C. Mommersteeg from the Center of Research on Psychology in Somatic Diseases, Tilburg University, The Netherlands, who has investigated associations between personality traits and coronary artery disease symptoms.\n\u201cPatients with normal coronary arteries or those with severe coronary artery disease seemed to get the most benefit in quality of life and did best,\u201d senior study author Dr. David E. Newby from University/BHF Center for Cardiovascular Science in Edinburgh, told Reuters Health.\n\u201cIn my opinion, CTCA does have added value in the diagnostic process (improved decision making), it is less invasive than coronary angiography (CAG), and can provide more clarity in the cardiac symptoms experienced by patients,\u201d Mommersteeg concluded.\n\u201cIf, however, a patient presents with atypical symptoms and is on no therapy, then the clinician needs to discuss with the patient the implications of potential CTCA findings, including nonobstructive disease that would mandate life-long preventative therapy,\u201d Newby said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is an independent source quoted. However, the story does not mention that the senior researcher quoted throughout the story had disclosed \u201chonoraria and consultancy from Toshiba Medical Systems,\u201d a manufacturer of CT scanners. There is also no mention of the funding of the study, though the funding description in the journal article says it came from a mix of public agencies and foundations, not from an industry source.", "answer": 0}, {"article": "Dr. Oken said the new study might have shown no benefit in 18-month-olds because effects in infants might be \u201chard to measure\u201d or \u201cit may be that the benefit of DHA is not as important as when you\u2019re 4.\u201d\n\nDr. Makrides\u2019s team plans assessments at 4 and 7.\nAnd the new study showed small reductions in postpartum depression in women with histories or high risk of depression.\nIts effect in supplements for children and adults is being studied, as well as whether supplements offer the same benefit as DHA-rich fish, like salmon.\nincreases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nShe said babies in her study might have received more DHA than those in this study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were several independent sources quoted/cited in the story. ", "answer": 1}, {"article": "The study was funded by the P.J.\n\"We can predict that about 15 out of every 100 people with a particular risk score will die of a heart attack, but the equations don't tell us which of those people will be one of the actual 15; they don't give us personalized information,\" says McEvoy.\nFor example, according to the researchers, those with systolic blood pressures below 140 millimeters of mercury and no calcium had an event rate of 12.7 events per 1,000 person-years, and similar people with systolic blood pressures between 140 and 159 millimeters of mercury had an event rate of 13.6 events per 1,000 person-years.\n\"If a health care provider wants to target blood pressure in a patient with traditional heart disease risk factors and above-normal blood pressure, he or she can look at coronary artery calcium to help with tiebreakerlike decisions,\" says J. William McEvoy, M.B.B.Ch., M.H.S., assistant professor of medicine and member of the Ciccarone Center for the Prevention of Heart Disease at the Johns Hopkins University School of Medicine.\nThe scans detect levels of calcium in the heart's arteries, and the physicians suggest those people with the highest calcium levels would benefit most from aggressive blood pressure treatment, whereas those with little or no calcium may not need to be treated as intensively, depending on their other heart disease risk factors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions who funded the study, but it omits one potential conflict of interest that was reported in the study: one of the authors serves on a speakers\u2019 bureau for GE Healthcare, which makes imaging equipment and software designed to detect coronary artery calcification. It\u2019s not a a major concern, but the lack of disclosure means the release doesn\u2019t quite meet our standard here.", "answer": 0}, {"article": "Foods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\nResearchers found the antioxidant activity of dark chocolate and cocoa powder was equivalent to or higher than that found in some other so-called \u201csuper fruit\" powders or juices, including acai berry, blueberry, cranberry, and pomegranate.\n\"When looking for a sweet snack, a square of dark chocolate might, in fact, be your healthiest choice!\"\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story discloses that the research was conducted by Hershey scientists, and it solicits comments on the findings from an expert who was not affiliated with the study. Although this is\u00a0enough for a satisfactory, we wish the story would have\u00a0sought out someone with a more skeptical take\u00a0on the results.\u00a0This\u00a0expert\u2019s comments \u2014\u00a0\u00a0\u201cWhen looking for a sweet snack, a square of dark chocolate might, in fact, be your healthiest choice!\u201d\u00a0\u2014 don\u2019t do much to help readers put the findings in the appropriate context.", "answer": 1}, {"article": "Two studies reported nearly 80% of Freespira-treated patients were panic attack free at 12 months post-treatment.\nFreespira is commercially available throughout the U.S. To learn more, visit http://www.freespira.com or contact info@pahealthsciences.com.\nThis latest study, conducted as part of the VITAL Program at Allegheny Health Network in Pennsylvania, also demonstrated a 50% reduction in healthcare costs in patients with panic symptoms 12 months after being treated with Freespira.\nDANVILLE, Calif., April 11, 2018 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the drug-free Freespira\u00ae treatment for panic attacks and other symptoms of panic disorder, today announced that another study has demonstrated clinically significant symptom improvement, with 80% of patients panic attack free one year after treatment.\nSymposium Chair David Tolin, Ph.D., Director of Anxiety Disorders Center, The Institute of Living, and Adjunct Professor of Psychiatry, Yale University School of Medicine, commented, \"Studies of the Freespira treatment have shown that this innovative approach to treating patients suffering from panic symptoms and panic attacks not only significantly reduces or eliminates these symptoms in approximately 80% of patients, but also results in meaningful reduction in health costs.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We are not told the source of money for any specific clinical trials. The release was written by Palo Alto Health Sciences, the company that sells the Freespira system. But we aren\u2019t told if the company\u00a0 supported any of the clinical trials financially and without access to the studies, we can\u2019t look up any potential conflicts of interest disclosures.", "answer": 0}, {"article": "MONDAY, Jan. 11, 2010 (HealthDay News) -- As a major organization of pediatricians considers revising its recommendations on circumcision of newborn boys, two new reviews of existing research offer conflicting conclusions about the bitterly debated procedure.\n\"There are some clear benefits to circumcision,\" he said.\n\"These may be considered unacceptable for an elective procedure,\" she said.\n\"There are some risks to circumcision, although the significant ones appear to be rare.\"\nTwo studies involved neonatal circumcision, and six involved older males, roughly 14 to 49 years old.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "For more information, visit http://medicine.\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\nWe wanted to understand the impact statin use has on surgical outcomes when repairing this type of aneurysm.\"\nAdditionally, the study showed that statin use also reduced post-surgical complications for patients with other health issues such as peripheral artery disease, a condition that causes arterial blockages of blood vessels in the limbs.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It appears this epidemiological study received no outside funding so we believe it\u2019s safe to conclude there is no conflict of interest.", "answer": 1}, {"article": "(That\u2019s a high dose; a 3 oz.\nfor more on that).\nThese are questions Kwong and others hope to answer with more studies.\nBased on analysis of their blood samples, the people taking omega-3 supplements also showed lower levels of inflammatory markers, which suggests that the fish oil may be working by reducing inflammation following a heart attack.\nNormally after a heart attack, part of the heart is starved of oxygen, and that portion never recovers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only the lead investigator, Dr. Raymond Kwong, was interviewed.", "answer": 0}, {"article": "Tomatoes are particularly high in the powerful antioxidant that acts like a sponge, soaking up rogue molecules called free radicals that if left unchecked can damage cells.\nBut the foods we eat are complex and filled with many nutrients, making it tough to prove what is really providing benefits.\nThe scientists found that those with the highest levels of lycopene were 55% less likely to have a stroke than those with the lowest amounts in their blood.\nElevated blood pressure is major risk factor for stroke.\nScientists then followed the men on average for more than a decade to record the number who had strokes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was\u00a0excellent input from independent experts on stroke and nutrition. This was a strength of the story.", "answer": 1}, {"article": "For their analysis, Gibbons and his colleagues looked at outcomes for each individual patient in published and unpublished trials testing the effects of six weeks of treatment with antidepressants versus placebo pills.\nThe researchers said they couldn\u2019t be sure there would be similar improvements with other types of antidepressants \u2014 especially given the more limited data in kids and the elderly \u2014 or that the longer-term benefits would be as clear.\nHowever, in the elderly the differences between the treatment and placebo groups were much smaller, and the researchers calculated that 17 older patients would have to be treated with Prozac for one to gain from it.\nSome of the study\u2019s authors have testified for or received funding from drug companies, though the report itself was funded by national health agencies.\n\u201cClearly the efficacy of antidepressants is age-dependent, (and) largest, most interestingly, in youth, which I don\u2019t think would be the mainstream view in psychiatry,\u201d Gibbons told Reuters Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story interviewed Irving Kirsch, frequently cited/quoted on antidepressant research issues.\nIt also did a good job of noting potential conflicts of interest.", "answer": 1}, {"article": "Article reference: R.M.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\nThe higher fluid rate also reduced the overall time of labor by an average of 64 minutes, and shortened the pushing phase by nearly 3 minutes, on average.\nWith the data pooled, the researchers could see a clear difference in outcomes for women in the two groups.\nOf those, about half (or 593 women) received IV fluids at a rate of 250 milliliters per hour, and the other half (622 women) received fluids at the lower rate of 125 milliliters per hour.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t note funding sources but the research report indicates that the scientists received no financial support, a situation not uncommon when analyzing existing data. The release does explicitly state that none of the investigators has a conflict of interest.", "answer": 1}, {"article": "\"We have noticed that the H-FABP level alone makes it possible to confirm that there is no risk of trauma in one third of patients admitted after a shock,\" enthuses Jean-Charles Sanchez.\nIt was still necessary to develop a device that could be used everywhere, quickly and simply, and that could be available in pharmacies or sports halls.\nAs their case is not a priority, it often takes a long time for the majority of patients to return home without risk of sequelae, except for bad memories.\n\"We wondered if it was possible to isolate certain proteins whose presence in the blood increases in the event of mild traumatic brain injury,\u00bb explains Jean-Charles Sanchez, professor at the Department of Internal Medicine of Specialties and the Biomarkers Centre of the Faculty of Medicine of the UNIGE.\n\"We are currently preparing an even more effective TBIcheck, which will allow 50% of patients to be sent home, but which requires an increase in the sensitivity of the test that receives the blood.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release stated that the test sponsor, the University of Geneva, holds a patent on the test which was developed by two of the study\u2019s authors who founded the company that will sell the test.", "answer": 1}, {"article": "\"This is hugely promising and very significant research,\" he tells WebMD.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentions that one source, Aaron J. Kowalski, PhD, is affiliated with the Juvenile Diabetes Research Foundation (JDRF), and says that he \"did not take part in the study.\" However, it does not disclose\u00a0that JDRF was a sponsor of the study, which\u00a0means that\u00a0Dr. Kowalski could be more likely than a truly independent observer to look favorably on the results.\u00a0\nThe story also did not identify\u00a0the financial\u00a0ties between one of the investigators quoted in the study and a study sponsor.", "answer": 0}, {"article": "A new non-surgical treatment for low-risk prostate cancer can effectively kill cancer cells while preserving healthy tissue, reports a new UCL-led phase III clinical trial in 413 patients.\nHe says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\nThe trial involved 47 treatment sites from ten different European countries, most of which were performing VTP for the first time.\nAt the moment, men with low-risk prostate cancer are put under 'active surveillance' where the disease is monitored and only treated when it becomes more severe.\n\"The fact that the treatment was performed so successfully by non-specialist centres in various health systems is really remarkable,\" says Professor Emberton, who is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the trial was funded by Steba Biotech, which holds the commercial license for the treatment. However, it does not mention that all of the study authors received compensation from Steba, and some also receive money from other biotech firms.", "answer": 0}, {"article": "Lauren Pestikas sits as she receives an infusion of the drug ketamine during a 45-minute session at an outpatient clinic in Chicago on July 25, 2018.\nExactly how ketamine works is unclear, but one idea is that by elevating glutamate levels, ketamine helps nerve cells re-establish connections that were disabled by depression, said ketamine expert Dr. Carlos Zarate, chief of experimental therapies at the National Institute of Mental Health.\n(AP Photo/Teresa Crawford)\n\nCHICAGO (AP) \u2014 It was launched decades ago as an anesthetic for animals and people, became a potent battlefield pain reliever in Vietnam and morphed into the trippy club drug Special K.\n\nNow the chameleon drug ketamine is finding new life as an unapproved treatment for depression and suicidal behavior.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nIts potential effects on depression were discovered in animal experiments in the late 1980s and early 1990s showing that glutamate, a brain chemical messenger, might play a role in depression, and that drugs including ketamine that target the glutamate pathway might work as antidepressants.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used a range of sources. It noted that one source, Yale University psychiatrist Gerard Sanacora, PHD, MD, has worked for companies seeking to develop ketamine-based drugs.\nOne quibble: The story devoted substantial ink to positive anecdotes. Was the reporter able to find patients with negative experiences involving ketamine? That would be interesting to know.", "answer": 1}, {"article": "But, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nDr. Schaefer pointed out that the kind of fish consumed is important.\nOther dietary intake and genetic propensities probably account for the rest.\nIn fact, fish intake accounted for less than half of the variability in DHA levels.\n\u201cThis study doesn\u2019t prove that eating fish oil prevents dementia,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story was based on information from an original research study and included quotes from the study senior author as well as material from an editorial about the research study.", "answer": 1}, {"article": "(Reuters Health) - A system of automated twice-daily texts and the ability to use text messaging to receive answers to questions about treatment helps relieve some of the stress of chemotherapy for women with breast cancer, researchers at the Fox Chase Cancer Center in Philadelphia reported Monday.\nThe text messages were most effective at reducing distress at the 2- and 4-month marks, according to the data presented by chief author Kuang-Yi Wen, an assistant professor in the Cancer Prevention and Control program at Fox Chase.\nAt the fourth month mark, \u201cthe gap was huge\u201d between the texting and control groups, she told Reuters Health in a telephone interview.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nSurprisingly, the older the patient, the greater the likelihood that she would text back, seeking more information.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources. While we couldn\u2019t identify any conflicts of interest, some of the researchers receive payments from industry. The article fell short by not indicating who funded the study.", "answer": 0}, {"article": "\"I have to repent.\n\"There's never been a study like this one,\" said Dr. Evan Hadley, director of geriatrics and clinical gerontology at the National Institute on Aging, which paid for the study.\n\"There is no data on non-obese humans,\" said Eric Ravussin, chief of health and performance enhancement at the Pennington Biomedical Research Center at Louisiana State University.\nBut Dr. Ravussin and Dr. Hadley cautioned that the study was preliminary, and that it did not prove that calorie restriction could make people healthier or add years to their lives.\nA six-month study in 48 people directed by Dr. Ravussin, being published today in The Journal of the American Medical Association, is the first rigorous test of calorie restriction in people who are overweight but not obese.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The main expert quotes in the story came from people with a vested interest in showing positive results. Evan Hadley of the National Institute on Aging (source of funding for the study) called the results of this pilot study \u201cstriking\u201d. In addition, an estimate for the number of individuals currently engaging in calorie restriction appears to have been obtained from the president of the Calorie Restriction Society. While this study is one of three pilots studies for the feasibility of calorie restriction in humans, no comments from the other research groups was included. ", "answer": 0}, {"article": "Previous studies using high-sensitivity cardiac troponin alone to rule out and rule in heart attacks have not consistently demonstrated sufficient safety to use in clinical practice.\n\"We have developed a simple lab score that is superior to using cardiac troponin alone for the identification of patients at low and high risk for heart attack or death at emergency department presentation,\" say Dr. Peter Kavsak, McMaster University, Hamilton, Ontario.\n\"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\n\"Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department\" is published August 20, 2018.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder\u2014the Canadian Institutes for Health Research\u2014is clearly identified.\u00a0 Conflicts of interest among the many coauthors, however, are not mentioned.\u00a0 The original research article offers a lengthy list of potential conflicts; for example, the two coauthors quoted in the news release have begun the process of patenting the laboratory scoring system discussed in the research.\u00a0 And the first author of the paper, one of those quoted, has received research funding and honoraria from a number of drug companies.", "answer": 0}, {"article": "While the procedure may look straightforward, it's extremely delicate, said Linda Cormier, a sales representative for Cambridge Endo, whose headquarters is in Framingham, Mass.\nWhile kidney cancer can have symptoms such as back pain and bloody urine, it's difficult to detect early, said Lee, who said about half of these tumors are found when people undergo X-rays for other reasons.\nHe also knew that the cancer happened to be a spot where the small instruments couldn't reach it, the operation might have to be much more extensive.\nThe hook, grasper and scissors are on the ends of shafts less than one-fifth of an inch wide.\nThe recovery has been pain-free, and the cancer hasn't returned, he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes no sources other than the surgeon who developed the technique. The story would have been much improved by including some perspectives from surgeons who do not have something to gain by what is said about the technology.", "answer": 0}, {"article": "The drug is approved for metastatic melanoma patients who show no response to other treatments and for advanced squamous non-small cell lung cancer (NSCLC) with progression on or after chemotherapy.\nWe have a real opportunity to change clinical practice for patients when other therapies have failed,\" said principal investigator Padmanee Sharma, MD, PhD, professor, Departments of Genitourinary Medical Oncology and Immunology and scientific director of the Immunotherapy Platform, part of MD Anderson's Moon Shots Program.\n\"The overall survival benefit shown in this study sets a new benchmark for therapeutic strategies for advanced RCC patients in need of a second-line therapy.\"\nAmong these patients, partial responses were observed in 24% of those treated with nivolumab and 5% of patients treated with everolimus; complete responses were observed in 1% (four patients) treated with nivolumab and fewer than 1% (two patients) treated with everolimus.\n\"Immunotherapy has long been believed to have the potential to make an impact in kidney cancer, but until now we had not been able to demonstrate such a significant survival benefit.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release fails to note that the study was funded by the manufacturer of nivolumab (Bristol Myers Squibb) and that Dr. Sharma is a consultant to the company. This is important context.", "answer": 0}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are solicited.\u00a0The only link included to an outside \u201csource\u201d is to the company that sells night milk.", "answer": 0}, {"article": "\"The interesting thing about the Safety Planning Intervention is that it is a relatively brief intervention and can be used in a lot of different [health care] settings,\" says Brian Ahmedani, director of behavioral health research at the Henry Ford Health System in Detroit, who wasn't involved in the new study.\nTwo-thirds of the people in the treatment group had used their safety plans, and they were also twice as likely to get follow-up mental health treatment when compared with the control group.\nIn other words, the intervention had nearly halved the risk of suicide in the six months after discharge.\nNow, a study shows that a simple intervention conducted by staff in emergency departments can reduce the risk of future attempts.\n\"When someone goes to the emergency room for a suicide attempt, they are at risk of another suicide attempt for the next three months,\" says Stanley.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two expert sources not involved with the study are cited, and we didn\u2019t detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "On the surface, this seems to contradict a U.S. trend toward holding off on surgery and monitoring men who have low-risk cancers with what's called \"active surveillance.\"\n\"Active surveillance means observing the patient in a proactive way, with regularly scheduled biopsies,\" he adds.\nFar from it.\nAll of them had early-stage prostate cancer at the beginning.\nSecond, the Swedish study compared radical prostatectomy to watchful waiting.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from the author of an editorial about the study reported on.", "answer": 1}, {"article": "Decipher was developed in partnership with the Mayo Clinic.\nThe Decipher results increased agreement in treatment recommendations between urologists and radiation oncologists, as the odds of a recommendation for adjuvant treatment by urologists vs radiation oncologists increased from 0.27 (95% CI, 0.17-0.44) to 0.46 (95% CI, 0.29-0.75) after results of the Decipher test were made available.\nIn addition, the 19% of the patients with the highest risk based on Decipher had a nearly 10-fold higher risk of distant metastases by 5 years.\n\"Conflicting treatment recommendations by different specialists looking at the same disease can be highly confusing for patients and is a problem for the health care system in general,\" said Paul Nguyen, M.D., of Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School.\nThe study was designed to evaluate how the Decipher Prostate Cancer Classifier, which predicts the risk of metastasis after prostatectomy, would impact adjuvant treatment recommendations made by urologists and radiation oncologists.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "GenomeDx Biosciences funded the research. The company\u2019s name appears 14 times in the release and its product shows up 29 times.\nBut while the study itself makes detailed and explicit disclosures about funding and potential conflicts of interest (some of the researchers are employees of the company), the news release doesn\u2019t. That\u2019s unfortunate. Prostate cancer is very prevalent, Medicare can\u00a0cover the cost of a Decipher test, and about\u00a0half of men who get prostate cancer are covered by Medicare \u2014 so GenomeDx Biosciences has a lot to gain from more widespread use of its product.", "answer": 0}, {"article": "Health officials in Norway recommend that pregnant women (and women who are trying to get pregnant) take 400 micrograms of folic acid per day.\nAs a result, a cup of enriched white long-grain rice now contains 797 micrograms of folic acid, for example, and a cup of Cheerios has 493 mcg, according to this report from the Harvard Women\u2019s Health Watch.\nThe study also looked at folic acid use later in pregnancy but found no correlation between that and the chances of a child developing an autism spectrum disorder.\nThe raw numbers also showed that women who took extra folic acid were less likely to have kids with Asperger syndrome or PPD-NOS, but when other factors were taken into account, the association was no longer statistically significant and could have been due to chance, the researchers found.\nAmong the 85,176 children in the study, 270 (or 0.32%) received an ASD diagnosis \u2013 114 (0.13%) had autistic disorder, 56 (0.07%) had Asperger syndrome and 100 (0.12%) were diagnosed with \u201cpervasive developmental disorder-not otherwise specified,\u201d or PPD-NOS.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Unlike the Reuters Health story (which quoted two independent sources), this one does not include comments from an independent source, just a quote from a journal editorial (and that quote doesn\u2019t directly address the quality of the evidence). The competing CNN.com story (also a blog post), reviewed a day earlier, had three independent sources.", "answer": 0}, {"article": "Less Fat.\u201d\n\nMeanwhile, Erchonia Medical, based in McKinney, Tex., has aggressively marketed its Zerona laser as \u201cthe first non-invasive body contouring procedure to effectively remove excess fat\u201d even though it has yet to receive F.D.A.\n(Such a delay is atypical, Ms. Riley said, adding, \u201cmost 510Ks are cleared within six months.\u201d)\n\nLast month, Dr. Robert B. Seltzer, a dermatologist in Pasadena, Calif., ran an advertisement in The Los Angeles Times for an informational seminar that called Zerona \u201cthe holy grail.\u201d In a phone interview, however, he said, \u201cI\u2019m not 100 percent convinced\u201d and planned to return his Zerona if he didn\u2019t continue seeing results in his patients.\nIn general, Karen Riley, a spokeswoman for the F.D.A., said \u201cit is considered off-label promotion if you are marketing to the public a use that has not been cleared.\u201d Steven Shanks, the president of Erchonia Medical, said, \u201cSince we use the exact same power for liposuction and breast augmentation, we self-certified the device.\u201d He said that in January 2009, the company had applied for a 510K clearance \u2014 which is based on the notion that an older device is substantially equivalent to a new one \u2014 and had yet to receive it.\nNonetheless, a brochure for Zerona states patients can collectively \u201close up to 9 inches without the pain or down time of surgery.\u201d Nationwide, medical spas, chiropractors, cosmetic surgeons, plastic surgeons and dermatologists now offer Zerona for $1,700 to $3,800 for six sessions.\nIf you\u2019re sedentary and not eating healthy food, he said, then once fat is leaked after Zerona treatments, \u201cyour body will just store it again.\u201d\n\nHow the body rids itself of fat, and how quickly, after any noninvasive body slimming procedure is unclear, said Dr. Lawrence S. Bass, a plastic surgeon in Manhattan who started using a Zeltiq device last July.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed ten sources\u2013two patients [one with good results, one with poor], one federal spokesperson, and seven doctors. Six of those doctors are not objective due to financial interest in the devices\u2019 efficacy. But one is fully independent. \nWith a story like this, which features new technologies, it\u2019s hard to find sources who know the devices well enough to understand them but have no interest in them. The reporter did a good job with sourcing under these circumstances.\u00a0 ", "answer": 1}, {"article": "PROVIDENCE, R.I. [Brown University] -- To the tantalizing delight of chocolate lovers everywhere, a number of recent studies employing various methods have suggested that compounds in cocoa called flavanols could benefit cardiovascular health.\nIn addition to Lin and Liu, the study's other authors are Isabel Zhang, Alina Li from Brown University, JoAnn Manson, Howard Sesso and Lu Wang from Brigham and Women's Hospital.\nThe greatest effects were seen among trial volunteers who ate between 200 and 600 milligrams of flavanols a day (based on their cocoa consumption).\n\"The treatment groups of the trials included in our meta-analysis are primarily dark chocolate -- a few were using cocoa powder-based beverages,\" Lin said.\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes the funding sources clear.\nIn addition to Lin and Liu, the study\u2019s other authors are Isabel Zhang, Alina Li from Brown University, JoAnn Manson, Howard Sesso and Lu Wang from Brigham and Women\u2019s Hospital.\nThe authors acknowledge funding from the National Institutes of Health including the National Heart, Lung and Blood Institute, the American Heart Association, and Pfizer. Co-authors at Brigham and Women\u2019s also noted receiving funding from Mars Symbioscience, a research segment of Mars, Inc., which makes chocolate products.", "answer": 1}, {"article": "Despite the fact that there have been no randomized controlled trials on whether metformin really can prevent cancer, researchers expressed excitement both over this animal study and previous epidemiological evidence pointing to this possibility.\nThe U.S. National Library of Medicine has more on metformin.\nInsulin may have a relationship with cancer.\nAnd when the drug was administered by injection, the improvement seen was 73 percent.\nAnderson Cancer Center in Houston, at a Wednesday news conference.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several sources interviewed \u2013 including one who appears to be independent of this research. ", "answer": 1}, {"article": "Chicago \u2014 Local bans on artery-clogging trans fats in restaurant foods led to fewer heart attacks and strokes in several New York counties, a new study suggests.\nHis study was published Wednesday in JAMA Cardiology.\nThe FDA in 2006 required them to be listed on food labels and the food industry has been switching to healthier oils.\nThis material may not be published, broadcast, rewritten or redistributed.\nTrans fats, also called partially hydrogenated oils, enhance food texture and structure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included two independent sources; we did not detect any undisclosed conflicts of interest.", "answer": 1}, {"article": "So researchers have been trying for decades to figure out how to build an inexpensive odor sensor for quick, reliable and noninvasive diagnoses.\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds.\nThe breath of diabetics sometimes smells of rotten apples, experts report; the skin of typhoid patients, like baking bread.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the sources have a vested interest in seeing these technologies come to market. Someone without such interests might have provided a helpful brake on the story\u2019s enthusiasm.", "answer": 0}, {"article": "For the current study, she and her colleagues sent out questionnaires to a representative sample of about 600 office-based doctors and hospital departments around the country.\nFirst, they might not know about the guidelines.\nThey asked doctors and staff what tests they used for cervical cancer screening and presented them with three patient scenarios.\nIf both tests are normal, those guidelines call for a three-year wait before the next screening.\nWomen should talk to their doctors about screening, especially if they think they are being screened too often, researchers added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert from the American Society for Clinical Pathology was interviewed \u2013 someone not involved in the study.", "answer": 1}, {"article": "MIT scientists find evidence that Alzheimer\u2019s \u2018lost memories\u2019 may one day be recoverable\n\n\u2019Siri, I want to commit suicide\u2019 and other statements likely to yield unhelpful responses from your phone\n\nRoots of Napoleon complex may be justified: Study finds short men get short of end stick in life.\nIn an editorial, Madhav Goyal and Jennifer A. Haythornthwaite of the Johns Hopkins University School of Medicine said that the mechanisms for why meditation might work on back pain is still a mystery but that this question is merely \"academic\" for many clinicians and their patients who need immediate relief.\nThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \"adverse event,\" most often an increase in pain due to yoga.\n\"These findings suggest that MBSR may be an effective treatment option for patients with chronic low back pain,\" the authors wrote.\nThe two wrote that despite this and other unknowns, the study provides \"a compelling argument for ensuring that an evidence-based health care system should provide access to affordable mind-body therapies.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Conflicts of interest don\u2019t appear to be an issue here, and the story includes\u00a0statements from\u00a0an accompanying editorial in JAMA, which was written by experts unaffiliated with the research. This squeaks by as Satisfactory, though it should be noted that most of this material was available via news releases (see below).", "answer": 1}, {"article": "\u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n\nThe new guidelines will lower the PSA level at which a biopsy should be considered, because, as Dr. Carter put it, \u201cthere\u2019s no level below which we can tell a man he doesn\u2019t have prostate cancer or life-threatening prostate cancer.\u201d\n\nAs one important trial showed, among men with a very low PSA \u2014 that is, a reading below the current cutoff of 4 \u2014 biopsies found that 15 percent had prostate cancer.\nThe new guidelines will no longer rely on a single reading.\nFor them, if other factors like prostate infection are not the cause of the high level, a biopsy is in order.\nPatrick Walsh\u2019s Guide to Surviving Prostate Cancer.\u201d\nHe explained that in men with an initially high level \u2014 say 10 or higher\u2014 velocity is not an issue.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several sources are quoted.\u00a0 ", "answer": 1}, {"article": "TUESDAY, Jan. 5, 2016 (HealthDay News) -- For the sixth year in a row, a panel of health experts has named the heart-healthy DASH diet the best overall eating plan, according to U.S. News & World Report's 2016 Best Diets ranking.\nWhen it comes to speedy weight loss, the HMR program and Biggest Loser diet shared the top ranking, followed by the Atkins diet in second place and Weight Watchers in third.\nOn the opposite end of the list, the Whole30 diet -- a 30-day program that bans processed foods, legumes, grains, dairy, alcohol and added sugar -- ranked as the worst overall diet on the list, the new report said.\nThe MIND diet includes some features of the DASH diet and Mediterranean diet, such as high consumption of fruits, vegetables and fish, but focuses on foods that promote brain health.\nThe DASH diet scored highest when it comes to healthy eating, followed by the TLC diet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted is the editor of USN&WR and that comment is lifted directly from the news release. It\u2019s standard journalism practice to have at least one outside expert provide additional context or any opposing views in a news story. Many news organizations require two or three.", "answer": 0}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an excellent job citing varied sources to provide the reader with multiple perspectives on this new breast augmentation technique.\u00a0 The story provides both positive and cautious testimonials from a range of cosmetic and reconstructive specialists, researchers and a patient who had the procedure.", "answer": 1}, {"article": "WEDNESDAY, Sept. 21, 2016 (HealthDay News) -- New guidelines issued by three leading cancer organizations suggest that more breast cancer patients should consider radiation therapy after a mastectomy.\n\"The guideline is timely,\" said Dr. Janna Andrews, an attending physician in radiation medicine at Norwell Health Cancer Institute, in Lake Success, N.Y. \"The field of post-mastectomy radiation is changing.\nFor instance, he explained, ''a woman 65 who has microscopic involvement in a single lymph node and an estrogen-receptor positive cancer would be very different from a 38-year-old who has three lymph nodes involved and so-called triple-negative breast cancer.\"\n\"In the past, if a woman had a small tumor, less than 5 centimeters, and not more than three or four positive lymph nodes, many doctors would say she does not need [post-mastectomy radiation therapy],\" she said.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites two experts: One who was involved in crafting the guidelines, and one who was not. More input from independent sources would have made the story stronger, but this is sufficient to merit\u00a0a Satisfactory rating.", "answer": 1}, {"article": "There has never been a safe and effective treatment.\nOn Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\nMost patients who got the active drug, dupilumab, instead of a placebo reported that the itching began to wane within two weeks and was gone in a few months, as their skin began to clear.\n\u201cI knew immediately I was on the drug\u201d and not the placebo, said Daniela Velasco, an event planner in Playa del Carmen, Mexico.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story fails to tell readers that every statistic and every expert quote is from sources funded by the companies, Sanofi and Regeneron, which are seeking approval to sell dupilumab. Not only were both trials funded by the companies, they largely controlled the writing of the New England Journal of Medicine article, to which the researchers \u201cprovided input\u201d and \u201cfinal approval\u201d of material produced with support from \u201cmedical writers who were paid by the sponsors.\u201d\nIn a startling omission, readers are not told that the lone \u201cindependent\u201d expert receives consulting and speaker fees from Regeneron. The story describes Dr. Mark Boguniewicz as \u201can atopic dermatitis expert at National Jewish Health and the University of Colorado School of Medicine who was not involved with the study.\u201d The story should have reported that Boguniewicz received more than $37,000 from Regeneron for consulting, speaking and travel reimbursements last year, according to Open Payments, a federal web site that collects reports of industry funding of physicians.", "answer": 0}, {"article": "I'm not waking up.\u201d\n\nSigns of sleep apnea, according to the National, Heart, Lung and Blood Institute, include:\n\u2022 Dry mouth or sore throat when you wake up\nInspire is an invasive procedure, so it is not recommended as a first-line treatment and not everyone is a candidate.\nThe drop in oxygen while sleeping is a significant risk factor for cardiovascular disease, say experts.\nA clinical trial of Inspire therapy found a 78 percent reduction in the number of sleep apnea events per hour for patients.\n\u201cI was exhausted all the time, from the time I woke to the time I went to bed,\u201d says Turner.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not disclose that the one study it relies upon as evidence\u00a0for Inspire\u2019s effectiveness was funded by the drug company.", "answer": 0}, {"article": "That's a potentially life-saving development.\n\u201cThe goal for most practicing allergists and for most parents is to get a child to the point where if there is an accidental ingestion of peanut it would not be as risky or life-threatening,\u201d said Dr. Amy Stallings, an assistant professor of pediatrics in the division of allergy and immunology at the Duke University Medical Center who is not affiliated with the new study.\n\u201cAnd the patch may be a way of doing this that is safer.\u201d\n\nThe patch study's results are promising, although researchers need to continue following the participants for another year, Sampson said.\nIt means that \u201cthey are not going to have to worry about traces of peanut in a package that came from a plant where peanuts were used or minor contamination of food in a restaurant,\u201d said the study\u2019s lead author, Dr. Hugh Sampson, a professor of pediatrics at the Icahn School of Medicine and director of the Jaffe Food Allergy Institute at Mount Sinai.\nIn the second phase of a drug trial, half of participants wearing the highest dose \u201cpeanut patches\u201d for a year were able to consume the equivalent of four peanuts without reacting, researchers reported Sunday at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does offer the reaction of a credible scientist who is not affiliated with the study. But it contains no information to help the reader assess possible conflicts of interest among the study authors. A MedPageToday story about the same study notes that Dr. Sampson, the lead study author quoted in the story, disclosed a relevant relationship with DBV, the company that makes the patch. The story also offers no explanation of who funded the trial (again, DBV).", "answer": 0}, {"article": "Still, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nThen after several months the tumors began to shrink.\nAll patients had inoperable cancers with widespread tumors after conventional treatment.\nAfter one year, the once palpable tumors were no longer detectable in diagnostic scans.\nA swollen lymph node on the neck was the only symptom Karen Anderson noticed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Story quoted one independent source in addition to one of the study co-authors. ", "answer": 1}, {"article": "The drug lorcaserin works on the serotonin receptor -- the same appetite-controlling hormone targeted by the notorious drug fenfluramine, the \"fen\" component of combination medication fen-phen.\nHe says that all the patients in the study were monitored closely for heart valve irregularities, and no difference was seen in the two treatment groups.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nAbout half the dieters who took lorcaserin for a year in the study lost at least 5% of their body weight, compared to 20% of dieters who took a placebo pill.\nAll the participants were counseled about diet and exercise.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It identifies conflicts in some cases, but there is no truly independent expert source quoted in the story \u2013 something that was badly needed.\u00a0", "answer": 0}, {"article": "Walnuts, that is.\nAnd a study of men attending a fertility clinic, published in May by the journal Human Reproduction, found that high intake of omega-3 fats was linked to more normal sperm size and shape, while high intake of saturated fats was related to lower sperm concentration.\nWalnuts are the only nuts with appreciable levels of omega-3 fatty acids, which some studies of male infertility have linked to better sperm quality, says researcher Wendie Robbins, PhD, of the UCLA Fielding School of Public Health.\nThe new study, funded in part by the California Walnut Commission, enrolled 117 men aged 21 to 35 who ate a typical Western diet.\nAug. 15, 2012 -- If you aspire to fatherhood, it might not hurt to go a little nuts.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentions that the study was partially funded by the California Walnut Commission, and it solicits a comment from an independent fertility expert. However, the expert\u2019s comments don\u2019t really add anything in the way of critical evaluation of the research or its implications. His quote\u00a0is generally supportive of the idea that diet plays a role in fertility, but offers nothing specific about the study. He could have been tapped, for example, to evaluate the clinical importance of the results. Tough call, but since he also offers advice suggesting that we\u2019re still a ways away from concrete recommendations regarding walnuts (\u201cFor now, the idea is to eat healthy with a varied diet.\u201d), we\u2019ll call it good enough for a satisfactory.", "answer": 1}, {"article": "Pooling data from 522 trials including nearly 120,000 patients, researchers found all drugs analysed were more effective than placebos in the treatment of adults with acute depression.\n\u201cAlthough antidepressants are of proven benefit\u2014as this study shows,\u201d she said, \u201cno doctor wants their patients to become reliant on medication.\u201d\n\nCarmine Pariante, a professor at the UK\u2019s Institute of Psychiatry, Psychology and Neuroscience and spokesperson for the Royal College of Psychiatrists, said the study \"finally puts to bed the controversy on antidepressants.\"\nThe results add up to a complex treatment picture for what authors called \u201cone of the most common, burdensome, and costly psychiatric disorders worldwide in adults.\u201d\n\nAntidepressants do not improve symptoms in about 40 percent of people, study author Andrea Cipriani of Oxford University told a press briefing.\nShe said in a statement: \u201cTaking antidepressants is frequently portrayed as a negative thing or something done only when other therapies are not available or have failed, but this in itself can add to the unfortunate stigma that sometimes exists around people with mental health conditions.\u201d\n\nBut she also urged caution.\nRead more: Trump Health Exam: President Still Taking Hair Loss Drug Even After Research Revealed Link to Erectile Dysfunction and Depression\n\nIn the U.S., the National Institute of Mental Health estimates 16.2 million adults experienced at least one major depressive episode in 2016.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides quotes from three psychiatrists who were not authors on the study, taken from an online source called Science Media Centre.\nIt doesn\u2019t say that one of them \u2014 Carmine Pariante \u2014 disclosed he received research funding from companies that make antidepressants. Pariante\u2019s quote seems to have provided the basis for the story\u2019s lead, which stated antidepressants \u201creally do work.\u201d", "answer": 0}, {"article": "WHAT: A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of \"good\" cholesterol, despite being treated with statins.\nNHLBI press releases and other materials are available online at http://www.\nHowever, a randomized study is needed to confirm these findings, according to the authors.\nJAMA Cardiology.\nARTICLE: M Elam et al.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes the funding sources for the study clear.", "answer": 1}, {"article": "In this study, researchers randomly assigned half of 263 healthy Swedish full-term newborns to have their cords clamped more than three minutes after birth.\nWhen separated by sex, only the boys showed statistically significant improvement.\nRabe's editorial accompanied the study published Tuesday in the journal JAMA Pediatrics.\nJaundice is treated with blue light therapy and rarely has serious complications.\nThe iron in the blood increases infants' iron storage, and iron is essential for healthy brain development.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story made very good use of independent sources beyond the study authors.", "answer": 1}, {"article": "More trials need to be done of this unique treatment, she added.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\n\"Of note is the reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins.\nMONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While this story includes quotes from experts not involved with the trial (unlike a Reuters story we also reviewed about a different trial of the same drug), it fails to tell readers that:\n\u2013\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 the trial was funded by Amgen\n\u2013\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Amgen led the design and conduct of the study\n\u2013\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 key researchers receive payments from Amgen, not only for research, but also to serve on boards and conduct outreach for the company.\nAll of this conflict of interest information is clearly listed at the end of the journal article that reports the trial results. It should have been included in the story.", "answer": 0}, {"article": "\"More often than not, the damage is due to benign (noncancerous) conditions such as enlarged prostate\" -- a condition called benign prostatic hyperplasia or BPH, Groskopf tells WebMD.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\nIf a man has any type of damage to the prostate, his PSA level can go up.\nThe PSA test detects prostate-specific antigen, a protein given off by all prostate cells.\nThis often triggers unnecessary biopsies and, sometimes, unnecessary surgery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story mentioned that the study was funded by the company that makes the test in question.\u00a0 The quote from the clinician from a for profit cancer treatment center barely qualified as an independent source. ", "answer": 1}, {"article": "Still, some researchers not involved in the study said the topic required more work.\n\u201cThe approach taken here is a very reasonable one that appears to have been successful,\u201d said Gary A. Giovino, a professor of health behavior at the State University of New York at Buffalo.\nThe smoking rate has declined substantially since the 1960s, but the pace of decline has slowed in recent years and health experts are trying to figure out how to get more smokers to quit.\nThe practice is common for smoking cessation therapies, said Robert West, director of tobacco studies at University College London, who was among the study\u2019s authors.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does clearly state the relevant study was funded by Pfizer \u2014 the drug company that makes Chantix. That\u2019s good. However, the story quotes only three sources. Two of them are authors of the relevant study. The third is David Abrams, who heads the Schroeder Institute for Tobacco Research and Policy Studies. A quick internet search finds that Abrams has also done smoking cessation research with funding from Pfizer. The story would have benefited from input from an expert with no ties to Pfizer\u2019s smoking cessation research.", "answer": 0}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Though the story included quotes from the author of a book on probiotics, it failed to include any insight from independent experts. \u00a0It should have included information from experts in the field without an association to a marketable product. \u00a0A link to something like NIH\u2019s site about probiotics would have lent some credibility to the information the story tried to impart.\n\u00a0http://nccam.nih.gov/health/probiotics/\nStating that the FDA is \"neutral\" obscures the fact that foods are not regulated in the same way as drugs.\u00a0 ", "answer": 0}, {"article": "A video of him walking with and without aid of the system can be found here: https:/ .\n\"I'll be able to walk for exercise and hopefully be able to walk into church and into a restaurant,\" McGlynn said.\nWith the technology switched on, he covered far more ground and his pace was twice as fast during his 30-week study.\nThe researchers are seeking funding to fit him with a permanent FES system in a clinical trial.\nThe pulses stimulate the nerves, which in turn stimulate the muscles in both of Bush's legs and McGlynn's left leg.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t note the funders but they are listed on the sidebar of EurekAlert!, a host site for the news release.", "answer": 1}, {"article": "\"In 2012, scientists took that particular frog and wanted to know why is it, why do these frogs keep milk fresh?\n\"Amphibians, especially certain groups of frogs, produce and store large amounts of antimicrobial peptides in specialized granular glands in the skin,\" said Louise Rollins-Smith, associate professor of pathology, microbiology, and immunology at Vanderbilt University School of Medicine.\n\"I need to come up with a strategy to deliver it systemically as well; maybe an injectable, which goes in the bloodstream and kills influenza viruses,\" Jacob mused.\n\"This peptide works by directly killing the virus, and it is specific for all influenza viruses that have a H1 type of hemagglutinin,\" Jacob said.\n\"We have identified a potentially new treatment for H1N1 human influenza virus, which is a peptide that comes from the skin of a frog from southern India,\" said Joshy Jacob , an associate professor in the Emory University School of Medicine's microbiology and immunology department, who led the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The primary source is clearly linked to the study, and two other sources are identified as independent of the research. Although the story does not mention funding sources, a news\u00a0release describing the research indicates that funding came from the university itself, not from external sources.", "answer": 1}, {"article": "It\u2019s a single.\u201d\n\nSaying that even a single was helpful, Dr. Kahl was part of a majority on the panel that recommended approval of the drug, 10 to 4.\nIn the clinical trial that led to approval of the drug, 27 percent of the 109 patients experienced a reduction in tumor size.\nIt says it will give the drug free to uninsured patients who cannot pay for it any other way.\nBut considering all the patients in the trial, only 12 percent had a reduction in tumor size that lasted for more than 14 weeks.\nSo the total cost of using Folotyn will be less than for many other drugs with lower monthly prices.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple stakeholders, including experts from the drug manufacturer, a large\u00a0insurance company, and lymphoma researchers. The provide valuable diversity of perspectives on this controversial issue.", "answer": 1}, {"article": "Researchers are separately looking at a drug called omalizumab (Xolair), approved by the U.S. Food and Drug Administration for the treatment of severe asthma, to see if it could help people with food allergies, too.\nDo not try the immunotherapy technique at home; these experiments are conducted under medical supervision.\nThese kids were severely allergic to cow's milk.\nStill, it did not eliminate all symptoms.\nThey're on the rise in the United States and no one knows why.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There wasn\u2019t any independent voice in the story.", "answer": 0}, {"article": "The drug, known chemically as denosumab, is widely considered to be Amgen\u2019s most important future growth driver and the FDA decision comes nearly two months ahead of the agency\u2019s expected action date of July 25.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\n\u201cMost of us certainly expected this drug to be approved,\u201d said Cowen and Co analyst Eric Schmidt, adding it was \u201ca surprise that it happened before\u201d July 25.\nHe estimates U.S. annual peak sales of $750 million to $1 billion in osteoporosis.\n\u201cIt\u2019s also superior to Zometa in its ability to delay subsequent events,\u201d Perlmutter said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "Lung cancer is the No.\n\u201cHowever, unique to this study, we have been able to report less advanced cancer in those who do develop cancer, a decreased frequency of squamous cell and small cell carcinomas, and improved survival, when controlled for stage, in people taking metformin and/or TZDs.\u201d\n\nThe team reviewed the medical records of 157 lung cancer survivors with diabetes.\nTZDs include GlaxoSmithKline\u2019s Avandia, known generically as rosiglitazone, and rival drug Actos, or pioglitazone, made by Takeda Pharmaceutical Co Ltd.\n\nMazzone said it may be possible one day to use metformin to prevent lung cancer in smokers.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\nWASHINGTON (Reuters) - Commonly used diabetes drugs such as metformin may help control lung cancer, and may help prevent it, U.S. researchers reported on Tuesday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Is it an independent source if the quote is copied from the press release? Perhaps that\u2019s a philosophical question. We gave it a pass on this one because we\u2019ve already dinged the story for relying too much on a news release in the criterion above.\nWe\u2019re given affiliations of the lead investigator and ACCP president. But it\u2019s unclear from the abstract whether A)\u00a0conflicts of interest were never disclosed by the researchers or B) that Dr. Mazzone disclosed that he had none. We\u2019re not told about the other authors\u2019 disclosures. From here we see no relevant problems, but it\u2019s another consequence of unpublished research: once it\u2019s peer-reviewed and published, we\u2019ll get clear, direct, and complete information about author conflicts of interest and study funding.", "answer": 1}, {"article": "That means lifestyle changes were twice as effective as medicine in delaying or preventing diabetes.\nFirst published on October 29, 2009 at 12:00 am\n\nCorrection/Clarification: (Published Oct. 30, 2009) The educational position of Elizabeth M. Venditti was reported incorrectly in this story as originally published Oct. 29, 2009, \"Pitt program to prevent diabetes shows promise.\"\nBut those who did undergo lifestyle changes showed such notable results that Pitt offered to enroll all 159 participants, including Mr. Held, in a lifestyle modification program.\nAs a result, Mr. Held, 78, of Whitehall, lost 20 pounds to his current weight of 146 pounds.\nThe blood-sugar level for a healthy adult, measured as milligrams of glucose per deciliter, is generally 70 to 100 mg/dl.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter spoke only with two study participants\u2013an area man who was a subject and a researcher who headed local efforts.\nThe local researcher does offer properly moderated comments, casting the study as suggestive of benefits under certain conditions.\u00a0 \nThis is a good start for sourcing but insufficient. At minimum the reporter should have spoken with one disinterested diabetes or obesity clinician or epidemiologist who could help put the findings in context.", "answer": 0}, {"article": "Moffitt researchers compared the overall survival and the time to diagnosis of a second tumor, if any, of 250,195 breast cancer patients who received either neoadjuvant or adjuvant radiation therapy.\nThe majority of patients who have early stage breast cancer have surgery to remove their tumor or a complete mastectomy.\nSurgery is commonly followed by radiation therapy, which has been shown to increase relapse-free survival.\nThey included female patients in the analysis who were diagnosed between 1973 and 2011 with early-stage breast cancer.\n6 cancer hospital in the nation and has been listed in U.S. News & World Report as one of the \"Best Hospitals\" for cancer care since 1999.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were noted and do not appear to be a conflict of interest.", "answer": 1}, {"article": "Cleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\n\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\nDec. 5, 2012 -- A breath test similar to the one used to determine when a driver has had too much to drink shows promise as a screening tool for cancer .\n\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful,\u201d he says.\nA person\u2019s breath contains a variety of chemical compounds, and it has long been recognized that certain illnesses can affect how the breath smells.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an expert who wasn\u2019t involved in the current study. However, since the source is involved in the development of a competing \u201celectronic nose\u201d technology, we don\u2019t think he qualifies as a truly independent voice.\u00a0Someone with expertise evaluating cancer screening evidence could have probably provided more useful context for readers.", "answer": 0}, {"article": "Together, stomach and oesophageal cancer account for around 1.4 million new cancer diagnoses each year worldwide [2].\nAmsterdam, The Netherlands: A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the oesophagus and stomach in a large patient trial presented at the European Cancer Congress 2017 [1].\nOver the next three years, the researchers will continue with a larger trial, using the test with patients who are being given an endoscopy for gastrointestinal symptoms but not yet diagnosed with cancer.\nBoth tend to be diagnosed late, because the symptoms are ambiguous, meaning the five-year survival rate for these two types of cancer is only 15%.\nThis means that not only was the breath test good at picking up those who had cancer (sensitivity), it was also good at correctly identifying who did not have cancer (specificity).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are named in a sidebar to the release on the EurekAlert! website. Ideally, the funders would also be listed in the release text so that when the release is republished that information is available.\nThe study abstract noted that the researchers stated they had no conflicts to declare.", "answer": 1}, {"article": "Additional information on the design of the trial can be found at www.clinicaltrials.gov .\n\"The study results show that CAM2038 provides rapid and extended blockade of opioid effects,\" said Fredrik Tiberg, President and CEO of Camurus.\nThe ability of CAM2038 to produce a long-lasting and robust blockade of hydromorphone-induced Drug Liking is especially encouraging,\" said Sandra D. Comer, Ph.D, Professor of Neurobiology, Columbia University.\n\"The current study demonstrated that weekly injections of CAM2038 produced significant and robust opioid blockade, a critical mechanism of efficacy for medications treating opioid dependence.\n\"We were pleased to be involved in the development of CAM2038 and are hopeful that it will serve as another safe and effective therapeutic option for patients with opioid use disorder.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No mention is made of funding, and the roles of the two academics quoted are never made clear. We are not told whether they helped carry out the study itself, whether they have a financial interest in the product, or whether they are speaking as disinterested expert observers.\nAccording to a speakers bio for a conference on treating opioid addiction, one of the experts quoted has financial ties to the sponsors of the drug tested. This conflict of interest should have been mentioned in the release.", "answer": 0}, {"article": "That\u2019s called secondary prevention.\nHere\u2019s the problem: The lower an individual\u2019s risk of a future heart attack or ischemic stroke, the less he or she will benefit from taking daily low-dose aspirin.\nIt is important to note that this draft recommendation applies to people who are not at increased risk for bleeding, have at least a 10-year life expectancy, and are willing to take low-dose aspirin daily.\nAlthough the totality of evidence is incomplete, it appears that aspirin has net benefits when the absolute 10-year risk of having a cardiovascular event is greater than 10 percent.\nIt is important to keep in mind that other therapies, such as statins, have also been proven to decrease the risk of cardiovascular events.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We applaud the breadth of sourcing in this piece. Readers are told that Kirsten Bibbins-Domingo, is the\u00a0vice-chair of the US Preventive Services Task Force, and she weighs in with her assessment. \u00a0Other physicians, however, seem independent of the USPSTF and are unlikely to be financially conflicted with the manufacturers of aspirin.", "answer": 1}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\nThe new pills also appear to be more effective than most current drugs.\nThe main benefit of the pills will be that they are easier to take.\nHe is excited about the new drugs, but cautious.\nDr. Peter Calabresi of Johns Hopkins University School of Medical is an author of one new study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used one independent expert source in addition to interviewing one of the study authors. ", "answer": 1}, {"article": "\u201cAnd when stimulation arrived in a good state, the average was about 15 to 20 percent worse than usual.\u201d\n\nDr. Doris Greenblatt, a psychiatrist who participated in the trial at Emory, said she sought the surgery because her epilepsy had long caused memory problems.\nThe new study is the latest chapter in an extraordinary, decades-long collaboration among cognitive scientists, brain surgeons and people with severe epilepsy being evaluated for an operation.\nThe preoperative \u201cevaluation\u201d is a fishing expedition of sorts, in which doctors sink an array of electrodes through the top of the skull and wait for a seizure to occur, to see whether it\u2019s operable.\nThis study used data from 150 patients, and had 20 collaborators from institutions around the country, including Emory University, the University of Washington, the Mayo Clinic and the University of California, San Francisco.\nIn a series of experiments, the researchers had patients memorize lists of words and later, after a distraction, asked them to freely recall as many of the words as they could.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The end of the scientific article that this story was based on notes that the two\u00a0senior authors are forming a company \u201cto develop and commercialize brain stimulation therapies for memory restoration.\u201d This should have been included in the story.", "answer": 0}, {"article": "Saturated fats are more likely to build up within artery walls and form plaques that can trigger heart attacks.\nThen, over the ensuing decades, it became clear as science progressed that there were multiple types of polyunsaturated fats, and these compounds potentially have distinct biochemical and health effects.\u201d\n\nThere has been some evidence to suggest that omega-6 fatty acids, for example, may trigger inflammation, a condition that is linked to an increased risk of heart problems, while omega-3 fatty acids, found in deepwater fish like salmon, tend to inhibit inflammatory reactions.\nFor more than three years, researchers at the time followed 458 men aged 30 to 59 years old who had a history of heart disease; about half were told to replace the saturated fats they consumed from animal and dairy sources with omega-6 linoleic acid, which is commonly found in safflower oil or margarines made from it.\nWe need to look at dietary patterns rather than individual nutrients or individual food components.\u201d\n\nWhether the association will change its advice about consuming linoleic acid isn\u2019t clear yet, but Ramsden says the results of the latest study \u201ccould have important implications\u201d for the way people eat if they want to stay heart-healthy.\nThe difference came down to the specific type of fats that make up these foods \u2014 animal and dairy fats tend to be saturated, which means all of the free bonds available in a chain of carbon atoms are bound to hydrogen atoms, while plant fats are unsaturated, meaning some of carbon atoms have double bonds with each other.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a comment from an American Heart Association spokesperson, who interestingly suggests that the new research may play a role in a re-analysis of the organization\u2019s diet guidelines. That\u2019s different than the stance taken by\u00a0the spokesperson contacted by HealthDay, who hinted that the results wouldn\u2019t have much effect on current recommendations.", "answer": 1}, {"article": "Depression risk was assessed using the Edinburgh Postnatal Depression Scale (EPDS) six weeks after childbirth.\nJoin the ANESTHESIOLOGY\u00ae 2016 social conversation today.\n\u201cLabor pain matters more than just for the birth experience.\nLike ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES16.\nFor more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the study.", "answer": 0}, {"article": "[3] Analysis only included cases occurring 10 days after receiving the vaccine to account for the incubation period of the Ebola virus.\nThe vaccine's manufacturer, Merck, Sharpe & Dohme, this year received Breakthrough Therapy Designation from the United States Food and Drug Administration and PRIME status from the European Medicines Agency, enabling faster regulatory review of the vaccine once it is submitted.\nIn addition to showing high efficacy among those vaccinated, the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach (so-called \"herd immunity\").\nThe rVSV-ZEBOV trial is funded by WHO, with support from the Wellcome Trust, the United Kingdom Department for International Development, the Norwegian Ministry of Foreign Affairs to the Norwegian Institute of Public Health through the Research Council of Norway, the Canadian Government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre and Department of Foreign Affairs, Trade and Development and M\u00e9decins Sans Fronti\u00e8res.\nIn case of Ebola flare-ups prior to approval, access to the vaccine is being made available through a procedure called \"compassionate use\" that enables use of the vaccine after informed consent.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release identifies the funding sources for the study, which included WHO and a number of government agencies from Canada, the United Kingdom, Norway, along with the international organizations the Wellcome Trust and M\u00e9decins Sans Fronti\u00e8res. The news release also identifies the organizations with which the study\u2019s research team members were associated, although it does not give any indication of the extent to which research team members or their organizations receive additional funding from Merck, which obviously stands to gain the most if the vaccine proves effective and is recommended for use by the World Health Organization.", "answer": 1}, {"article": "\u201cYou really can\u2019t see it.\n\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\nAnd it needs to be strong enough and elastic enough that it actually affects the recoil of the skin.\u201d\n\nThat, he said, \u201cis the challenge I put to them.\u201d\n\nDr. Robert Langer, a biomedical engineer who is a professor at M.I.T.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly uses sources beyond those provided by the news release. It also gets applause for pointing out clearly the connection between the researchers and the companies licensing the product saying, \u201cAll of the authors on the new paper have an equity interest in Living Proof and so, indirectly, in Olivo,\u201d (the two identified companies).\u00a0 NBC\u2019s story on the same research\u00a0didn\u2019t\u00a0make this financial connection nearly as clear.", "answer": 1}, {"article": "\"I think it is an important landmark to see some cancer patients respond to a gene therapy -- finally,\" said Patrick Hwu, a physician and gene-therapy researcher at the University of Texas M.D.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nAt least five years would need to pass before such a declaration would be considered.\nIn the study, Rosenberg and his colleagues took lymphocytes from the blood and inserted into them genes for a receptor capable of \"recognizing\" a protein on melanoma cells called MART-1.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This article included helpful comments from clinicians familiar with the experimental approach but who were not directly involved with this particular study. They help to temper the enthusiasm of the principal investigator on this project and to balance the piece.", "answer": 1}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly identifies the lead author of the study when quoting him and cites two additional experts who have no affiliation with the study.", "answer": 1}, {"article": "Records covered the use of both low- and high-dose aspirin (ranging from 75 milligrams to 500 milligrams), so-called \"nonselective\" NSAIDs (such as ibuprofen [Advil] and naproxen [Aleve]), and both older and newer types of COX-2 inhibitors.\n\"Now we have a better understanding that inflammation also plays a significant role in cancer formation and even skin cancers,\" he said.\nThe researchers pointed out that the NSAID-cancer connection could be affected by a range of lifestyle factors they did not account for, such as an individual's specific skin type or sun exposure patterns.\nMeanwhile, Dr. William Ting, a private practice dermatologist in San Ramon, Calif., praised the study despite agreeing that many factors are at play when it comes to skin cancer formation.\nOn that front, long-term users and those who took NSAIDs at relatively higher doses appeared to benefit from the strongest protective effect, suggesting that when it comes to skin cancer risk reduction, more NSAID use is better.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert was quoted, although unfortunately his comments tend to reinforce the story\u2019s exuberance rather than restrain it. Why this private practice dermatologist was chosen as the one independent expert is unknown.\u00a0 Does he have a research background?\u00a0 The quote doesn\u2019t offer any evaluation of the evidence.", "answer": 1}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story references a written editorial published to accompany the story in JAMA, which we\u2019ll consider good enough for a satisfactory rating here. Actually interviewing someone not affiliated with the research might have yielded additional interesting insight on this topic.", "answer": 1}, {"article": "Dr. Louis Jacques, director of the coverage and analysis group at the Centers for Medicare and Medicaid Services, said cost was not a factor and that the agency had reviewed products approved by the F.D.A.\nOne criticism of the drug was filed by a law firm, Willkie Farr & Gallagher, on behalf of a client who the law firm said wanted to remain anonymous because of the \u201cpublic vilification of anyone that questions Provenge.\u201d\nThe 10 voting members, mainly doctors and health policy experts, averaged 3.6 on the question of how much confidence they had that there was adequate evidence to conclude that Provenge significantly prolongs survival.\n\u201cOne has to wonder if today\u2019s meeting is about something other than science, namely the cost,\u201d Brad Loncar, an investor in Dendreon whose grandfather died of prostate cancer, told the Medicare Coverage Advisory Committee on Wednesday.\n\u201cI\u2019ve never seen anything like this.\u201d\n\nExelixis will now add many prostate cancer patients to the midstage clinical trial from which the results were drawn, said Michael M. Morrissey, the company\u2019s chief executive.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted at least one clinical expert who did not appear to have ties to the study reported on or the company that makes the drug. It would have greatly improved this story if insight from an expert on prostate cancer, especially castration-resistant prostate cancer had provided a context for evaluating the benefit of the drugs reported on \u2013 including quality of life issues.", "answer": 1}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not provide any independent input about the therapeutic claims of rivastigmine for treating dementia in people with Parkinson\u2019s. ", "answer": 0}, {"article": "The drug\u2019s manufacturer hopes prisons will be the gateway to a larger market.\nIt gets better really fast.\u201d\n\nVivitrol targets receptors in the brain\u2019s reward system, blocking the high and extinguishing urges.\nThere\u2019s widespread agreement that counseling, support groups and treatment for underlying problems such as depression are crucial for Vivitrol patients, said Dr. Joseph Garbely of Pennsylvania-based Caron Treatment Centers, which supports medication-assisted treatment and prefers Vivitrol.\nThe results, published in March in the New England Journal of Medicine, have been promoted by the drugmaker, Ireland-based Alkermes, as it markets Vivitrol to U.S. correctional systems.\n\u201cThere\u2019s been pushback with other medications, people saying, \u2018We\u2019re just changing one drug for another.\u2019 That argument goes out the window when you\u2019re talking about a blocker\u201d like Vivitrol.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The company that owns Vivitrol is clearly identified, as are a couple of sources who are studying the drug, including the first author of the NEJM study. At least one source, who expresses concern about the company\u2019s vigorous marketing to prisons, appears to be independent. The National Institute on Drug Abuse, which supported the research discussed in the NEJM article, is also identified.", "answer": 1}, {"article": "For more information, go to UHhospitals.org.\n\"These survey results show that something as simple as a change to a more elegant delivery system that is easier to use and not messy might empower more post-menopausal women to seek prescription treatment for VVA, and perhaps help them stay with the application guidelines for longer,\" said study first author Sheryl Kingsberg, PhD, Division Chief, OB/GYN Behavioral Medicine, UH Cleveland Medical Center; Professor of Obstetrics and Gynecology and Psychiatry, Case Western Reserve University School of Medicine; and first author of the survey analysis.\nA new investigational delivery method for localized vaginal estrogen therapy that utilizes an applicator free softgel to alleviate moderate-to-severe vaginal pain during intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), received high rates of patient satisfaction among post-menopausal women, according to post-trial survey results published in the journal Menopause.\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\nThe main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that Dr. Sheryl Kingsberg, the study\u2019s first author, has been a consultant for TherapeuticsMD, which manufactures the active ingredient in the softgels, and for a number of other pharmaceutical companies. It did not mention that several of the study\u2019s other authors also have received research support or consulting fees from TherepauticsMD.\nThis study carries a strong imprint of its funder, the manufacturer. The acknowledgement in the study notes that even the authorship of the paper was contracted out to a professional medical writing firm, which is a practice that is often criticized. The journal manuscript acknowledged it; the news release could have as well.", "answer": 0}, {"article": "As of last month, 354 people who got CTs had died of lung cancer, compared to 442 who got ordinary X-rays.\nIt is also possible the scans will turn up tumors that would never have killed the patients, and that some people will undergo unnecessary surgery if they are screened.\nThe study sponsored by the U.S. National Cancer Institute is the first to show that people can be screened for lung cancer, akin to mammograms for breast cancer and tests for colon and prostate cancer.\n\u201cWe will have what breast cancer has now, which is a lot of survivors.\u201d\n\nThe researchers have some caveats.\nThey do not know whether the radiation from the CT scans may raise the risk of cancer, and they do not know what the study means for light smokers, younger people, or those who have never smoked.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study raises many questions that will likely be debated for years by the experts. The failure to provide a single independent voice to the discussion is curious to say the least.", "answer": 0}, {"article": "\u201cOur analysis firmly establishes that controlling LDL over time translates to fewer deaths in this population.\u201d\n\nProfessor Sir Nilesh Samani, medical director at the British Heart Foundation, said: \u201cThis research further demonstrates the benefits of statins for people who have high levels of cholesterol in their blood.\n\u201cThe role of cholesterol in causing heart disease has been disputed by some, but this paper provides yet more evidence of the link, and the benefits of statins to prevent heart disease.\u201d\nRay added: \u201cThis is the strongest evidence yet that statins reduce the risk of heart disease and death in men with high LDL.\nThey found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\nThe 20-year project examined data from 2,560 men taking part in a randomised clinical trial to test the effects of statins versus a placebo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t note how the study was funded through Sanofi, a company that makes, markets, and sells statins, Furthermore, most of the authors disclosed that they have accepted either grant money or fees from major pharmaceutical companies. In fact, five out of the the eight authors had or have a financial relationship with Sanofi.", "answer": 0}, {"article": "By the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\nIt's unclear how many relapsed after quitting the pill.\nThe drug costs at least $350 a month, plus the price of doctor's visits.\nAt the start of the study, they drank, on average, 11 standard drinks daily.\n\"And all the drinking variables changed in the right direction.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Experts in the field who were not associated with this study were quoted in the story.\u00a0 In addition, the story clearly indicated that the study was funded by the maker of the drug.", "answer": 1}, {"article": "Or she could allow doctors to implant two long, thin electrodes deep into her brain, along with an electrical generator about the size of an iPod in her chest.\n\"This (the JAMA study) is the largest, most complete and thorough analysis of deep brain stimulation to date,\" Hiner said.\nThe results come at time when a growing number of people are reaching their late 50s and early 60s, when they are most likely to be diagnosed with the disease, which affects between 500,000 and 1.5 million Americans.\nIn a sense it's a field of science that works backward: Stimulation is applied to the brain, some people get better, and doctors try to figure out why.\nThe six-month study, which involved 255 people, found that those who underwent surgery had 4.6 more hours each day of good control of their symptoms than those who got the best drug therapy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed one patient with a self-reported positive outcome, and four medical specialists. \nThe reporter\u2013eventually, in the last phrase of the story\u2013mentions that the research was paid for partly by the maker of the deep-brain stimulation device.\u00a0 \nOn balance, the sourcing of this story is acceptable.\u00a0 ", "answer": 1}, {"article": "LaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\n\u201cWhat makes our study stronger than those others is that we used a device that was able to measure all of the movements we do in our daily lives,\u201d she says.\n\u201cWe\u2019ve always been told that this type of activity isn\u2019t enough to do you good,\u201d says LaCroix.\n\u201cWe know that people of different ages need different amounts and intensities of exercise to get the same result,\u201d she says.\nBased on the data from the women\u2019s activity trackers, the researchers found that those who got at least 30 minutes of light physical activity a day were 12% less likely to die, compared to those who got less.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No outside sources are cited in the story, nor does the story make clear who funded the research (addressing potential conflicts of interest).", "answer": 0}, {"article": "Coffee or tea?\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nThere's a growing body of research to suggest that both are probably good for you.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nWe've heard a lot about the health benefits of tea, especially green tea.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no quotes from any investigators in the field. Even if Dr. Weil\u2019s expertise is taken into account as author of the piece, that is still only a single-source perspective. ", "answer": 0}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted sources beyond only the study authors. Some of the study authors disclosed relationships with medical device companies such as Boston Scientific (which makes the Watchman device mentioned in the story); however, a quick search did not reveal any conflicts of interest for Drs. Giri \u00a0and Koren, the two expert sources who are directly quoted by the story.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It is an inherent weakness of this sort of first-person reporting that there is an absence of independent sources. All but one of the physicians quoted in the story were personally involved in the reporter\u2019s case. The one exception is a vascular surgeon who strongly advocates for broader carotid artery screening. There are no quotes from experts who were members of the task force that recommended against widespread screening.", "answer": 0}, {"article": "New clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\nThe study participants, who were currently experiencing mild-to-moderate depression, had a mean age of 52, with 38 percent of them male.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nParticipants in the active arm of the study received 248 milligrams of elemental magnesium per day over six weeks, while those in the control arm received no treatment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release didn\u2019t mention either the funding sources or address conflicts of interest. These were noted in the study and could have been easily included in the release.", "answer": 0}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, it should have been made clear that the May 2018 \u201clarge-scale test\u201d is unpublished and funded by the test sponsor.\nThe same goes for the Genecept paper that is cited by the company\u2019s VP: it\u2019s an industry-sponsored review paper \u2014 not original research \u2014 and cannot\u00a0 make claims about improved clinical outcomes or reduced overall medical costs from genetic testing.\nWe were pleased to see two independent sources cited, one of which provided a critical perspective.", "answer": 0}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This one barely squeaks by. There is one independent comment on the trials from\u00a0David Felson at the Boston University School of Medicine, who said that the lack of a control group \u201craises questions of whether it is cupping that is really working or if it has a placebo effect.\u201d But more detailed comment on each of the cited studies\u2019 shortcomings and limitations would have been hugely helpful in producing a more balanced view on the benefits of cupping.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly identifies sources affiliated with the two companies that make the radiation device, as well as a researcher who is funded by one of the companies. \u00a0These sources are offset by references to the JAMA Dermatology editorial and by comments from one of the editorial authors.", "answer": 1}, {"article": "\"Sure.\nBut we were surprised by how healthy he seemed seven months later, in August 2008, when we visited with him and his wife Marianne at their home in Erie, Pa.\n\n\"I must say you look like a completely different person to me.\n60 Minutes decided to keep track of Kanzius and his invention, so we followed him for over a year, as he pushed to speed up the research on his machine and fought to slow down his own cancer, which was killing him.\nWhen 60 Minutes met him back then, he showed Stahl how the radio waves - transmitted across a small field - created enough energy to light up a fluorescent bulb.\nSo even though he had been feeling good for awhile, he admitted there was always fear his disease could take a turn for the worse.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n \nThat journalists with the resources and airtime available to \u201c60 Minutes\u201d failed to present any independent experts or even to let viewers know about the patent and other financial interests of the people interviewed is just mind-boggling. Given the fact that there are literally thousands of scientific articles on related topics, it is mystifying that Stahl failed to present an iota of context or perspective from anyone without a personal stake in the device. (The comments of the pathologist in the piece don\u2019t count, since he had no way of knowing whether the blood cell counts he looked at displayed the effects of Kanzius\u2019s device or merely the expected results of chemotherapy.)\n It is impossible to watch this story without reaching the conclusion that Stahl and the producers made a conscious decision to exclude any independent experts.", "answer": 0}, {"article": "So he fears that fat injections for breast enlargement could increase unnecessary biopsies.\nThe pleased mother of three in the news clip said her breasts grew \u201covernight,\u201d which is misleading.\nThis kind of is a two-fer: trim fat where you don\u2019t want it and put it where you do.\nThat hasn\u2019t stopped Dr. Todd Malan, a board-certified ob-gyn in , Ariz., who is the surgeon in the ABC news clip, from anointing himself the \u201cFirst in U.S. to perform Stem Cell Enhanced Breast Augmentation!\u201d on his Web site.\nBut when they can\u2019t, biopsies may be done.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story included more than one independent expert and it identified the professional affiliations and some of the financial arrangements between experts who were quoted and companies or practices that profit from fat grafting.", "answer": 1}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any experts who could have provided some valuable perspective on the importance of the new findings. This is particularly important for industry sponsored trials.\u00a0 ", "answer": 0}, {"article": "All participants took calcium and vitamin D as well.\nAccording to an editorial accompanying the study, this complication occurs in about 5 percent of cancer patients who are taking a high-dose bisphosphonate (Zometa or Aredia) to control or prevent spread of malignancy to the bone.\n\"These were patients with severe periodontal disease but who were otherwise systemically healthy,\" said study senior author Dr. Laurie K. McCauley, chair of the department of periodontic and oral medicine at the University of Michigan in Ann Arbor.\nOne report describes the case of an 88-year-old woman who had been taking the bisphosphonate alendronate (Fosamax) since suffering a hip fracture 10 years earlier.\n\"I think that it's really an important important proof-of-concept that you can inject locally and get a response,\" said Dr. Rena D'Souza, chair of biomedical sciences at Texas A&M Health Science Center Baylor College of Dentistry in Dallas.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites the editorial and one source who seems independent. It fails to mention that Forteo\u2019s dad, Eli Lilly, provided financing for this study, and one author disclosed an additional financial relationship with Lilly.\n More of the perspective from the editorial would\u2019ve been a great asset to this article, as it provided a realistic appraisal of the study\u2019s results.", "answer": 0}, {"article": "Subsequent actions by PGC1-alpha then stimulate cells to produce more mitochondria.\nThe two studies were started and performed independently, Dr. Auwerx said, though he obtained supplies of resveratrol from Sirtris, which was co-founded by Dr. Sinclair, and he has become a scientific advisor to the company.\nThe principal theory developed by Dr. Guarente and others is that the sirtuins somehow sense the level of energy expenditure in living cells and switch the body\u2019s resources from reproduction to tissue maintenance when food is low.\nThe developing buzz over sirtuin activators has captivated some scientists who do research on the aging process, several of whom are already taking resveratrol themselves.\nOne serious uncertainty is whether, in the mouse experiments, resverattrol in fact acted through the sirtuins or by some other unknown mechanism.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story quoted several scientists not directly associated with the particular studies or companies mentioned, there was no balance to the perspectives represented.\u00a0 The story would have been greatly imporved if it had included some serious comment about the ramifcations of the scientific observations reported.", "answer": 0}, {"article": "The state's most comprehensive health sciences university, LSU Health New Orleans includes a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\nThis relationship strengthens the researchers' hypothesis that the lower pole ligaments stretch at a significantly slower rate than the upper pole ligaments.\nBelieving that disruption of the lower suspensory ligaments may be a critical factor because they are stronger than the upper sensory ligaments, the researchers conducted a retrospective review of 208 patients who underwent breast reduction surgery from 2008-2015, studying the results in 400 individual breasts.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention a funding source but that\u2019s understandable since the published study clearly states there is no conflict of interest and no funding source.", "answer": 1}, {"article": "It\u2019s better to avoid fatty food altogether.\nTaking a statin is a rational way of lowering some of the risks of eating a fatty meal.\u201d\n\nStill, Peter Weissberg, medical director at the British Heart Foundation (BHF) health charity, said Francis\u2019 idea should not be taken too literally.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\n\u201cThey are not a magic bullet.\u201d\n\nA study in June in the Archives of Internal Medicine suggested, in fact, that statins do not save lives in patients without heart disease, although they may prevent some non-fatal heart attacks.\nFrancis\u2019 team \u2014 who worked independently and had no funding from the drug or food industries for their research \u2014 used data from a previous large study to quantify how a person\u2019s heart attack risk increases with their daily intake of total fat and harmful trans fats.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The use of independent voices here is key, and the reporting team did a lot of reading to give readers a fuller picture of the debate about statins. If people could hear more doctors saying that a particular drug is \"not a magic bullet\" in news stories, we probably would pay far less for the drugs that do work well.", "answer": 1}, {"article": "Pregnant women are generally advised to limit their consumption of certain types of fish like swordfish and tuna because they contain mercury.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nMore than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nBut many other types are considered safe, especially smaller fish like sardines that are not at the top of the food chain and therefore not likely to accumulate mercury and other contaminants from eating other fish.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly explains who funded the study, and includes an independent source. But it doesn\u2019t note the extensive conflicts of interest reported by the lead author who\u2019s quoted in the piece:\nDr. Bisgaard reports receiving consulting fees from Chiesi Pharmaceuticals and Boehringer Ingelheim, and Drs. Bisgaard and B\u00f8nnelykke report being named on a pending patent related to the prevention of childhood asthma through FADS genotyping and the assessment of blood levels of eicosapentaenoic acid and docosahexaenoic acid in pregnant mothers.\nThe patent filing related to genetic testing is particularly relevant, given that the researcher advocates genetic testing and testing of fish oil levels in pregnant women to determine who might benefit most from supplementation.", "answer": 0}, {"article": "For example, over 6 years of follow-up, no ovarian cancer cases were seen among BRCA2 mutation carriers who underwent salpingo-oophorectomy, compared with 3 percent of carriers who did not undergo the procedure, the researchers report.\nRoughly half of the women in the study had undergone either mastectomies (surgery to remove their breasts) or salpingo-oophorectomies (surgery to remove the ovaries and fallopian tubes) between 1974 and 2008, in order to proactively lower their risk of cancer.\n\"One of the main messages of our study is that salpingo-oophorectomy should be part of any management plan for any woman who is found to have these genetic mutations,\" said Rebbeck.\nWomen who carry these mutations have a lifetime risk of breast cancer of anywhere between 56 percent to 84 percent, according to the researchers, whereas the risk for ovarian cancer ranges from 36 percent to 63 percent for BRCA1 mutation carriers and 10 percent to 27 percent for BRCA2 mutation carriers.\nHowever, \"what our findings show is that women who choose to have these surgeries will reduce their risk of dying of breast or ovarian cancer by about 70 to 80 percent, which is pretty profound,\" said study senior author Dr. Timothy Rebbeck, a professor of epidemiology at the University of Pennsylvania School of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story includes comments from an author of an editorial in the journal who was not involved in this study. Although the story does not report financial or other information about the sources, the study was funded by a variety of grants from public agencies and foundations and neither the researchers nor the editorial writers reported any relevant financial disclosures.", "answer": 1}, {"article": "Researchers recommend large-scale clinical trials to confirm that nighttime fasting results in favorable changes to biomarkers of glycemic control and breast cancer risk.\nThe data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.\n\u201cThis is a simple dietary change that we believe most women can understand and adopt.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper.\nThose who reported longer fast durations also indicated they consumed fewer calories per day, ate fewer calories after 10 p.m. and had fewer eating episodes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are clearly stated at the end of the press release. There are no apparent conflicts of interest.", "answer": 1}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story could have brought in some independent voices, which is why we gave it an unsatisfactory here. It did note that one of the authors had been a paid consultant for the pharmaceutical industry and for Weight Watchers, which was good to see disclosed.", "answer": 0}, {"article": "And while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\n\"It seemed like they probably had a couple of cheat days here and there,\" she says of the data.\nKrista Varady, an outside researcher who studies intermittent fasting (not the same as intermittent dieting) and weight loss at the University of Illinois, believes the results were significant.\n\"I was really impressed that they still saw almost a two kilogram weight loss during that last period at the end of the four months,\" she tells Newsweek.\nOne group of men followed the diet, which reduced calorie consumption by about one-third of their individual needs, for 16 weeks straight.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article included an \u201coutside researcher\u201d who has some bona fides in the study of intermittent fasting, albeit not dieting, and quotes her essentially saying that the findings were significant and made sense to someone who studies dieting challenges.", "answer": 1}, {"article": "Wilmington, DE, December 17, 2018 - The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or \"knocking out\" a gene in cancer tumors that helps the tumors develop resistance to the drugs.\nBut he said some patients with non-small-cell lung cancer, the most common form of lung cancer, are resistant to chemotherapy agents used to treat the disease or develop resistance after being exposed to the drugs.\n\"We think it's best to start with CRISPR therapies that involve relatively conservative uses of this powerful tool,\" Dr. Kmiec said.\nThe Gene Editing Institute is the only research institute of its kind in the nation based within a community health care system.\n\"This approach can also hopefully help contain costs and provide a level of safety and reliability that is reassuring for patients and increases the chance that insurance companies will provide coverage.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders (NIH and State of Delaware) are noted on a sidebar on the EurekAlert! site which hosts the release. We encourage news release authors to include funding sources in the body of the release as well.\nThe authors did not report any conflicts of interest.", "answer": 1}, {"article": "But scientists also realized it could have other uses.\nIt\u2019s a fairly dramatic effect.\u201d Mice also showed increased oxygen consumption, higher levels of physical activity and more heat production in beige fat (which dissipates energy around the body).\nAnd the population that could be most benefited by this could be post-menopausal women.\u201d\n\nCommenting on the research, Tim Speckor, Professor of Genetic Epidemiology at King\u2019s College London, U.K., says: \u201cIt\u2019s a nice mouse study that seems to work\u2014whether it works in humans is another matter.\u201d\nAs a result, they started considering it as a potential treatment for osteoporosis, particularly in post-menopausal women\u2014a period when women lose bone mass fairly quickly.\nIn trials on mice, the antibody was found to increase bone mass and reduce adipose tissue (fat)\u2014and while human studies are some way off, the findings could lead to new treatments for weight loss and osteoporosis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does cite one independent source, but only in the very last paragraph. The story does not tell readers who funded the research, nor does it note that a provisional patent has been filed for the antibody. This is particularly relevant given that the scientist listed as inventor on that patent, and who would therefore receive royalties and/or licensing fees if the antibody is commercialized, is the same researcher who is quoted throughout the article about the potential impact of the antibody.", "answer": 0}, {"article": "The research is so early that the drug hasn't been named.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nThe current treatment for chronic HCV -- intravenously administered peg-interferon and ribavirin -- cures about half of people with genotype 1 who take it.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nIn preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "According to disclosure statements from a 2008 CME program,\u00a0Dr. Bruce Bacon, an expert source for this story, received research funding from Bristol Myers Squibb, which is developing the experimental drug being discussed. He also is a consultant to drug companies developing competing drugs for hepatitis C.\u00a0To avoid the appearance of a conflict of interest it is desirable to identify\u00a0relationships such as these clearly.\u00a0 This story fails to do so.", "answer": 0}, {"article": "Bishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\n\"There's a variety of methods you can use to achieve the strengthening technique,\" says Jason Grandeo, a physical therapist at Body Dynamics, Inc. in Arlington, Va.\nAnd he didn't want to give it all up due to a \"spot of pain\" in his elbow.\nAnd the FlexBar makes it simple to do this kind of stretch.\n\"This wasn't a traumatic injury,\" explains Holzman.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes the involvement of the FlexBar manufacturer in the study that is referenced.\u00a0It also quotes an independent\u00a0physical therapist who suggests there are other ways to achieve the effect attributed to the FlexBar.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes the lead author of the recent study, Claudia Henschke. The story should have quoted other clinicians or researchers who could have provided some much needed balance.", "answer": 0}, {"article": "\"One of the concerns about taking aspirin remains the potential for intestinal bleeding.\nProfessor Elwood said: \"Our review, based on the available evidence, suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.\nProfessor Elwood added: \"While there is a desperate need for more detailed research to verify our review and to obtain evidence on less common cancers, we'd urge patients diagnosed with cancer to speak to their doctor about our findings so they can make an informed decision as to whether or not they should take a low-dose aspirin as part of their cancer treatment.\"\nThe team's review looked at all of the available data including five randomised trials and forty two observational studies of colorectal, breast and prostate cancers.\nIn a systematic review of the available scientific literature a team from Cardiff University's School of Medicine found a significant reduction in mortality and cancer spread by patients who took a low-level dose of aspirin in addition to their cancer treatment (average study follow-up length over 5 years).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and potential conflicts of interest weren\u2019t noted in the release. The study, published in PLoS ONE,\u00a0 however, declares no conflicts of interest and \u2014 curiously \u2014 no support or funding, either.\nBut since this type of study is based on analyzing others\u2019 results, we\u2019ll go out on a limb to assume that the researchers\u2019 institutions backed it in the form of their usual salaries. In any case, we want to see these items clarified in news releases.", "answer": 0}, {"article": "\u201cAre DORAs the perfect hypnotics?\nOnly long-term use in large numbers of insomnia patients will reveal whether these drugs will be preferred to GABAergic hypnotics, and whether they produce rare complications, including narcolepsy-like symptoms in predisposed individuals,\u201d Mignot wrote.\nMost sleep aids, including Sanofi\u2019s Ambien or Sunovion Pharmaceuticals\u2019 Lunesta, act on a key neurotransmitter in the brain called GABA.\nIn the study, rats given GABA blockers were less likely to recall the objects than those given DORA-22.\nGABA receptors are important to many brain regions, including those important for cognition, which is likely why common sleep aids can cause memory loss and attention problems.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does report that the researchers work for Merck, the company applying for approval to sell a similar drug. The story would have been better if it had included comments from an interview with an independent source (as did the HealthDay story we also reviewed), rather than just an excerpt of a journal commentary article.", "answer": 1}, {"article": "MS is an autoimmune neurodegenerative disorder that affects nearly 2.5 million people worldwide.\nThe drug tested in the trial, clemastine fumarate, was first identified as a candidate treatment for MS in 2013 by UCSF's Jonah R. Chan, PhD, Debbie and Andy Rachleff Distinguished Professor of Neurology, vice chief of the Division of Neuroinflammation and Glial Biology, and senior author of the new study.\nIn addition to Green and Chan, authors (all at UCSF) include Jeffrey M Gelfand, MD, MAS; Bruce A Cree, MD, PhD, MAS; Carolyn Bevan, MD; W. John Boscardin, PhD; Feng Mei, PhD; Justin Inman; Sam Arnow; Michael Devereux; Aya Abounasr; Hiroko Nobuta, PhD; Alyssa Zhu; Matt Friessen, PhD; Roy Gerona, PhD; Hans Christian von B\u00fcdingen, MD, PhD; Roland G Henry, PhD; and Stephen L Hauser, MD.\nTo enhance the power of their study, the researchers used a \"crossover\" design: they divided the patient population in two and gave the drug, blinded to both participant and researcher, to one group, and a placebo to the other for 90 days; then they switched between the two groups, giving a placebo to the first group and the drug to the other for the next 60 days.\nThe researchers said that the Phase II results, published online on 10 October, 2017 in The Lancet, are the first in which a drug has been shown to reliably restore any brain function damaged by a neurological disease in human patients.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions that work was funded by the Rachleff Family.\nHowever, five out of 18 authors, including the first author, had multiple competing interests, mostly in the form of personal and consulting fees from the world\u2019s largest pharmaceutical companies according to the original journal report. Those conflicts should have been mentioned in the news release.", "answer": 0}, {"article": "\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\nThe next step was to ask whether those variants really could predict who had prostate cancer.\nBut the men in this study had an average age of about 65, when the disease is less common and more likely to kill.\nIn fact, no one knows what their effect is.\nThat resulted in the discovery, by several groups of investigators in Iceland and the United States, of the gene variants, small alterations in gene sequences.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from experts in the field who were not connected to the study reported on.", "answer": 1}, {"article": "But after controlling for those risk factors, \"the difference [in brain aging] is still there so we conclude that omega-3 fatty acids likely explain them,\" Tan said.\nAnother possibility is that the slight mental decline that the people in the older brain group were experiencing caused them to eat less healthy omega-3-rich foods, instead of vice versa.\nThe researchers found that those with the lowest levels of omega-3s had worse scores on tests of visual memory, attention and abstract thinking than people who ranked in the top 75 percent for fatty-acid levels.\nThe researchers took into account various health and lifestyle factors, including age, education and body mass index, to explore whether other differences among the people with low levels of omega-3s could help explain their more rapid brain aging.\nFind out more about brain health at the Alzheimer's Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert, and there were no conflicts that should have been identified.", "answer": 1}, {"article": "While studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.\n\u201cThese findings on the longer-term benefits at seven years post-treatment are really exciting,\u201d Bhalotra said.\nMore than 400 million people worldwide report episodes of depression, at a global cost of around \u00a3600bn in 2010.\n\u201cThis is an important study for the impact on mothers with depression but there are global implications for the treatment of all human beings suffering from depression.\nThe first group were also more likely to be employed and have control over household spending.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote anyone independent of this study; this would have been very useful to include considering this is unpublished data (as far as we can tell).", "answer": 0}, {"article": "For the study, researchers looked at data on 27,347 women ages 50 to 79 who joined two WHI trials between 1993 and 1998 and were followed through 2014.\nThey took hormones or a placebo for five to seven years and were followed for a total of 18 years altogether.\nOne limitation of the study is that the WHI didn\u2019t look at different dosages of hormone pills, and the findings may be different for other dosages or different types of therapy such as gels or creams or skin patches.\n\u201cHormone therapy has been in and out of favor - first it was good for all menopausal women, then it was dangerous for all women,\u201d McNeil said.\nAfter 18 years, including both the treatment period and a decade or more of follow-up, women\u2019s age when they joined the study no longer appeared to significantly influence death rates.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent source and there does not appear any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Lozano acknowledges that retrieving childhood memories, which he says has occurred in about one-third of his patents \u2014 requires lofty voltages that he would be uncomfortable sending patients home on.\nThe technique is also approved for obsessive-compulsive disorder and is being looked at for a number of other brain disorders, including depression, chronic pain and, as in Lozano's work, dementia.\nReferring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nRight now, deep brain stimulation is used primarily to treat Parkinson's disease and tremor, for which it's approved by the Food and Drug Administration.\n\"We also know that in patients who receive stimulation there is an increase in glucose utilization in memory areas of the brain,\" he says, a finding that could mean there's a way to overcome some of the damage from Alzheimer's.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites multiple sources but fails to mention research funding or potential or conflicts of interest. Notably, it omits the fact that one researcher at the center of this story, University of Toronto neuroscientist Andres Lozano, M.D., has a financial interest in the deep brain stimulation as co-founder and director of Functional Neuromodulation Inc, which makes the deep brain stimulation device.", "answer": 0}, {"article": "Earlier this year, dementia overtook heart disease as the leading cause of death in England and Wales.\nDavid Reynolds, chief scientific officer at Alzheimer\u2019s Research UK, said: \u201cIt is conceivable that changing brain cell rhythms could be a future target for therapies, but researchers will need to explore how light flickering approaches could not only reduce amyloid in the visual area of the brain but in those areas more commonly affected in Alzheimer\u2019s.\u201d\n\nThe authors suggest that it may be possible to take a multi-sensory approach, using a combination of flashing lights and vibrating chairs.\nEd Mann, an associate professor of neuroscience at the University of Oxford, said: \u201cI was surprised, and it\u2019s exciting, that such a simple stimulus can target a molecular pathway and have such an effect in an hour.\u201d\n\nQuestions remain, however, about whether boosting gamma oscillations and sweeping amyloid plaques out of the visual brain region would help with memory, which is centred in the hippocampus, or broader cognitive abilities.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\nThe study, in mice, found that exposure to flickering light stimulated brain waves, called gamma oscillations, that are known to be disturbed in Alzheimer\u2019s patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The senior author of the study is cited (and\u00a0her quote came from an unattributed news release, see last criterion, below), but so are other researchers. Independent sources appear to have been consulted.\u00a0The story also notes that the author has formed a company to pursue this, which is an important conflict of interest disclosure.", "answer": 1}, {"article": "The treatments that were compared and ranked included acetaminophen; ibuprofen; intra-articular (IA) or joint injections of cortisone; platelet-rich plasma (PRP); hyaluronic acid (HA); several NSAIDs, such as naproxen, celecoxib, and diclofenac; and both oral and IA placebo.\n\"Because knee OA has both a high disease burden and high treatment costs, additional prospective studies using similar outcomes, timelines, and measures of clinically important changes are needed,\" explained Dr. Jevsevar.\n\"While the information in this analysis is helpful to physicians, patients also can benefit from these findings and use it with their doctors to weigh all possible treatment options.\"\n\u2022 HA injections did not achieve a rank in the top five treatments for pain, function, or combined pain and function.\nAn analysis of 12 articles also found that results with HA are not significantly different from those with IA placebo for treatment of knee OA.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release identifies only where the authors work. It does not include the disclosures listed in the journal article. These disclosures should have been included in the news release.", "answer": 0}, {"article": "The fact that recognizing and acknowledging a familiar person is such...\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\nA little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes three of the authors of a published study; in addition it contains interview material from a person being treated that had Parkinson\u2019s disease as well as another clinician who did not appear to contribute to this publication.\nHowever \u2013 there was no one with an expertise in the miminally concious state not connected with this particular\u00a0technology in some way who appears to have been interviewed for this story.\u00a0 ", "answer": 0}, {"article": "RANKL and RANK also link sex hormones to breast cells by providing signals telling the breast cells to grow.\nIn 2010, Josef Penninger, the scientific director of IMBA in Vienna and his team have shown that sex hormones can trigger breast cancer (Schramek et al., Nature) through proteins called RANKL and its receptor RANK, which are key factors in bone metabolism.\nMoreover, the scientists \u2013 together with colleagues in Barcelona and from the CIMBA* consortium mapping more than 23,000 women \u2013 showed that genetic variants in the RANK gene are associated with a higher risk of developing breast cancer in women who carry BRCA1 and also BRCA2 mutations.\nUntil now, prophylactic surgery is the only procedure which significantly reduces the breast cancer risk, but which is also often associated with postoperative complications.\nIn the current study, Verena Sigl, graduate student from Penninger's research group, showed that blocking the RANKL/RANK system in BRCA1 mutant mice led to largely normal mammary glands whereas invasive carcinomas could be found in the control group.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the research received funding from the U.S. Department of Defense but it doesn\u2019t provide other important information that adds transparency. According to the published study, the Institute of Molecular Bioltechnology has applied for a patent on using RANKL inhibition to block breast cancer and that Amgen, Inc. (the maker of denosumab) provided RANK-Fc and financial support for the study.", "answer": 0}, {"article": "Awair is the first smart air quality device that monitors, analyzes and provides feedback to improve the air you breathe.\nDry air can also exacerbate some illnesses and can be a problem as well.\u201d\n\nDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves, but these aren\u2019t the worst culprits, Lahita said.\nWhile breathing fresh, clean air can boost productivity, sleep and overall health, not everyone can live in the great outdoors and it\u2019s difficult to know just how clean the indoor air in your home or office is.\nIt analyzes the data in real-time and gives an Awair score on a 0 to 100 color-coded scale, 0 being the worst air quality.\nAs soon as you see other colored (amber and red) dots show up on top of the green dots, your environment is getting off the healthy ranges whether it being temperature, humidity, CO2, VOCs, and dust,\u201d Ronald Ro, the CEO and co-founder of Bitfinder Inc., the makers of Awair, told FoxNews.com.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is satisfactory, but barely. The story does quote a physician with no obvious ties to Awair about how air quality may affect health. What\u2019s not clear is why the reporter chose to spoke to the physician, who specializes in rheumatism, arthritis and related ailments. More importantly, the story is missing any independent sources who can weigh in on Awair, or how effective it may be at reducing any kind of health risk.", "answer": 1}, {"article": "Hamilton, ON July 19, 2016 -- The first steps towards developing a vaccine against an insidious sexual transmitted infection (STI) have been accomplished by researchers at McMaster University.\nThe study was funded by the Canadian Institutes for Health Research.\nThe next step is more testing for effectiveness against different strains of Chlamydia and in different formulations.\n\"The vaccine would be administered through the nose.\n\"Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,\" said Bulir, who just finished his PhD in medical sciences at McMaster.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the Canadian Institutes for Health Research funded the study.", "answer": 1}, {"article": "Nadworny, who now works as a public policy advocate for people with disabilities, had knee replacement surgery last April.\nThe vast majority of joint-surgery patients report much less pain and greater mobility afterward, with success rates topping 95 percent, according to the American Academy of Orthopedic Surgeons, a physicians organization.\nLast year, the average salary for joint-replacement specialists topped $575,000, reported the Dallas consulting firm Merritt Hawkins & Associates, compared with just over $230,000 for family doctors.\nSo I said, \u2018OK, let\u2019s get this done.\u2019 \u201d\n\nSmith, who played hockey in college and as an adult and spent years lifting heavy equipment on building sites, plans to return to his job this spring.\n\u201cThe person who struggles is the one who\u2019s done long-distance running for years and just doesn\u2019t want to give it up.\u201d\n\nTechnology could eventually change that.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story admirably reported the generous pay of doctors who do joint replacements: \u201cLast year, the average salary for joint-replacement specialists topped $575,000, reported the Dallas consulting firm Merritt Hawkins & Associates, compared with just over $230,000 for family doctors.\u201d\nBut the story doesn\u2019t tell readers that the only doctor it quotes \u2014 orthopedic surgeon David Mattingly, M.D. \u2014 has received $160,000 from joint maker DePuy Synthes, a division of Johnson & Johnson, in recent years, according to the database Open Payments.\nIt would have been good to quote a doctor who doesn\u2019t make a living doing these surgeries (e.g. an internist or sports medicine doctor who treats hip and knee osteoarthritis).", "answer": 0}, {"article": "DUARTE, Calif. -- A City of Hope-led study found that the use of low-dose aspirin (81mg) reduces the risk of breast cancer in women who are part of the California's Teacher's Study.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\n\"We already knew that aspirin is a weak aromatase inhibitor and we treat women with breast cancer with stronger aromatase inhibitors since they reduce the amount of estrogen postmenopausal women have circulating in their blood,\" said Bernstein.\nNow that we have some data separating low-dose from higher-dose aspirin, more detailed research can be undertaken to understand the full value of low-dose aspirin for breast cancer prevention,\" said Clarke.\"\nOther collaborating authors include Alison J. Canchola, M.S., and Lisa M. Moy, M.P.H., from the Cancer Prevention Institute of California, and Susan L. Neuhausen, Ph.D., The Morris & Horowitz Families Professor in Cancer Etiology & Outcomes Research, Nadia T. Chung, M.P.H., and James V. Lacey Jr., Ph.D., M.P.H., from City of Hope.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly identifies the sources of funding. It does not address conflicts of interest, but there do not appear to be any relevant conflicts of interest. Still, the release would have been stronger if it had stated that explicitly.", "answer": 1}, {"article": "For the new analysis - the first of its kind - the research team looked at dietary data from 160,191 women and assigned inflammation scores based on 32 food components that the women reported consuming in the three months prior to their enrollment.\nVedat Yildiz of Ohio State's Center for Biostatistics also worked on the study, which was supported by the National Heart, Lung and Blood Institute and the U.S. Department of Health and Human Services.\nDietary information as well as data on bone density and fracture were collected from a large group of the participants in the Women's Health Initiative, the largest study of postmenopausal women's health undertaken in U.S. history.\nThe study, led by Tonya Orchard, an assistant professor of human nutrition at The Ohio State University, appears in the Journal of Bone and Mineral Research.\nThe findings suggest that women's bone health could benefit when they choose a diet higher in beneficial fats, plants and whole grains, said Orchard, who is part of Ohio State's Food Innovation Center.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release explains that the study was funded by\u00a0the National Heart, Lung and Blood Institute and the U.S. Department of Health and Human Services.", "answer": 1}, {"article": "NEW YORK (Reuters) - An insomnia drug being developed by Merck & Co was significantly better at improving sleep than a placebo in a mid-stage study, according to data presented on Wednesday.\nHe said the 80 mg dose was likely more than most people need.\nIn the one-night measure, patients who took the highest dose of the Merck drug slept 12.2 percent more of the eight hours than those who got a placebo.\nOrexin is a neuropeptide that is believed to play a key role in regulation of the brain\u2019s sleep/wake process.\nAt 20 mg the difference was 10.4 percent and at 10 mg, 4.7 percent.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources, and they are sorely needed.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\n\u2022 Available downloadable B-roll, animation and images to this news tip are on the right column of the tip link https:/\n\u2022 For more news at AHA International Stroke Conference 2018, follow us on Twitter @HeartNews #ISC18.\nIt is already well-established that the benefit of clot removal declines each hour during the first 6 hours after symptoms are detected.\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\nStatements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions that the DAWN trial was funded by\u00a0Stryker Neuroendovascular. What it did not mention is that Stryker is a company that produces medical devices, and their device for clot removal was the only one used in the trial. Presumably, the good results from this trial will lead to an uptick in their product sales. Indeed, the news release from Stryker contains a lot more information about the specific product compared to this news release.\nWhile many journalists reading the release will understand who Stryker is and why this represents a conflict of interest, consumers reading a reposted version of the release may not have that context. For their benefit, it would be better to spell things out directly.", "answer": 1}, {"article": "Newswise \u2014 CHAPEL HILL, NC \u2013 For patients whose hearing is considered \u201ctoo good\u201d for traditional cochlear implants, but whose hearing loss is too advanced to benefit from hearing aids, there hasn\u2019t been a device to meet their needs.\n\u201cThe technology is remarkable and so were the results.\u201d\n\nThe implant relies on two auditory technologies \u2013 the SYNCHRONY cochlear implant that stimulates the auditory nerve for high-frequency hearing loss and the EAS audio processor, which has a built-in acoustic amplification for low-frequency hearing loss.\nThe SYNCHRONY EAS implant best assists people whose hearing loss is referred to as \u201cski-slope\u201d hearing loss, based on the steeply sloping image that appears on an audiogram when a patient has more trouble hearing higher-frequency sounds.\nBut a hearing implant system that just received FDA approval will now meet that previously unmet need and benefit those patients, according to Harold C. Pillsbury, MD, chair of the Department of Otolaryngology/Head and Neck Surgery at the UNC School of Medicine.\nWhile 2 percent of adults aged 45 to 54 have disabling hearing loss, the rate increases to 8.5 percent for adults aged 55 to 64.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release needed information about funding sources for the clinical trials. In addition, the release does not explain the quoted source\u2019s relationship to the study (although it is implied that he is helping to lead it).", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sources do not appear to have conflicts of interest, and none are noted. The CDC and VP of Pediatric AIDS Foundation seem to be balanced sources without ties to pharmaceutical companies. How the nevirapine studies are funded would be good to note.", "answer": 1}, {"article": "The research falls short of concluding marijuana helps wean people off opioids - Vicodin, Oxycontin and related painkillers - and heroin, though.\nI couldn't get anything done,\" Ham said.\n\"Now, I actually organize volunteers, and we have a donations center to help the needy.\"\nHam gave it a try in 2013 and said the pain is under control and she hasn't gone back on the opioids.\nWhat we're doing today is the healer.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There\u00a0sourcing is a strong point for the story. Also,\u00a0there are no apparent conflicts of interest.", "answer": 1}, {"article": "The researchers wanted to evaluate whether in a group of women suffering from severe menstrual pain, aged between 18 and 34, self-acupressure would be more effective at achieving a sustained reduction in menstrual pain than usual care alone (e.g.\nA total of 221 participants were randomly assigned to one of two treatment groups, both of which received a study app and short introduction.\nOnly 25 percent of women in the control group reported a similar reduction in pain intensity at both the 3-month and 6-month marks.\nIn contrast to acupuncture, this technique can be used as a form of self-care and is suitable for use at home.\nIn: American Journal of Obstetrics and Gynecology, Volume 218, Issue 2, February 2018, Pages 227.e1-227.e9.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t say how the research was funded. The last line of the release notes the trade name of the app used in the study but not the developer.", "answer": 0}, {"article": "Italian researchers conducted a phase three study that included 281 women with breast cancer, aged 18 to 45 years and who had not experienced menopause.\nAn accompanying editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy should not be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease.\nWhile most breast cancer is diagnosed at later ages, about 6% of women learn that they're ill before age 40 - when they are still of childbearing age.\nEarly menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nAmong the women who had received triptorelin, the rate of early menoapuse was 8.9%, which is 17% lower.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cited an editorial that accompanied the journal article.\u00a0 However, there was no indication of potential conflicts or lack of conflicts of interest, despite disclosures stated in the journal article.", "answer": 0}, {"article": "\u201cIs it once a week, or every couple of years?\nThere\u2019s a huge range in my clinical experience.\u201d Carpenter, a physician, says research has not found any safety issues for patients returning for additional treatments, but cost is a factor.\nWith the nation\u2019s health-care spending expected to top $2.7 trillion this year, the battle over paying for rTMS demonstrates why it is so difficult to rein in health-care costs.\nOne key measure \u2014 known as the \u201cnumber needed to treat\u201d \u2014 found that one patient became symptom-free for every 12 who were treated.\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story represents both sides of this debate fairly, with the perspective of advocates from the device industry balanced against that of insurer-affiliated skeptics who say the evidence is weak. The story failed to clear the bar, however, when reporting comments from a researcher at Brown University who has conducted studies of rTMS. Although her comments are cautious and raise important questions about the treatment, the story did not disclose that she has been a consultant to, and received grant support from, rTMS device manufacturers (as indicated in this slide set from a recent presentation). It would have been nice to hear from an expert with no meaningful financial stake in this issue.", "answer": 0}, {"article": "(R) Anthony L. Asher, MD, FACS, medical director at Carolinas HealthCare System's Neurosciences Institute and the senior author on the report, and (L) Stuart H. Burri, MD, chairman, department of radiation oncology at Levine Cancer Institute, spearheaded an international, multi-institutional, randomized trial that will ultimately improve the standard of care for patients with a specific type of brain tumor, brain metastases, by reducing the toxicity of their treatment without reducing the effectiveness.Video - http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/CarolinasHealthCareSystem.mp4Photo - http://photos.prnewswire.com/prnh/20160726/392955\nThe study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.\nAnthony L. Asher, MD, FACS, medical director at Carolinas HealthCare System's Neurosciences Institute and the senior author on the report, and as well as Stuart H. Burri, MD, chairman, department of radiation oncology at Levine Cancer Institute, began their research on this subject over 10 years ago in Charlotte, North Carolina.\nThe technique was pioneered at Levine Cancer Institute and they are looking to expand and further validate the approach with the National Cancer Institute.\n\"In the past, clinicians who treated patients with brain tumors seldom used sophisticated techniques like neurocognitive tests to evaluate patients' daily function in response to various therapies,\" said Dr. Burri.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is not identified in the release. The release also makes no mention of conflicts of interest, but the journal article disclosure section notes only that one of the authors (not mentioned in the release) receives some industry funding.", "answer": 0}, {"article": "About another third reported less frequent episodes of low back pain, \"maybe once a day,\" says researcher Thomas Lehnert, MD, an assistant professor of radiology at Frankfurt University in Germany.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nAnd 7% had no improvement or their pain got worse.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD.\nIn the study, 119 people (37%) reported no pain at six months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a spokesman for the American Academy of Orthopedic Surgeons and it is implied but not stated that this person was not associated with the study. The spokesman provided important context.", "answer": 1}, {"article": "Colic is usually defined as excessive and inconsolable crying for at least three hours a day for more than three days a week over more than three weeks.\nA study of probiotics, which are reputed to help digestion, found that 95 percent of infants given L. reuteria probiotics seemed to reduce their average crying time compared to 7 percent of babies given simethicone, which is marketed to relieve gas under the brand names Mylicon and PediaCare Infants' Gas Relief.\n\"It's reasonable for parents to consider those kinds of interventions for which there is some suggestion of benefit but no known risks,\" said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Steven and Alexandra Cohen Children's Medical Center of New York.\nMONDAY, March 28, 2011 (HealthDay News) -- Fennel extract, herbal tea and sugar water relieved colic in some infants better than a placebo, according to a new study that reviewed clinical trials of alternative remedies for colic.\nThis implies the improvement may \"have more to do with the therapeutic effect of touch than the actual therapy itself,\" Dr. Edzard Ernst, of the department of complementary medicine at Peninsula Medical School, Universities of Exeter and Plymouth, in the United Kingdom, and colleagues wrote in the report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story tapped two independent experts: Dr. Andrew Adesman, chief, developmental and behavioral pediatrics at the Steven and Alexandra Cohen Children\u2019s Medical Center of New York and\u00a0Dr. Ari Brown, an Austin pediatrician and co-author of\u00a0Baby 411. Both provided good context and words of caution for concerned parents.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe drugs are injected into the eye and work by inhibiting vascular endothelial growth factor (VEGF), a substance that can promote abnormal blood vessel growth and leakage.\nAt the end of the trial, average visual acuity was 20/32 to 20/40 among participants in all three groups.\nBy two years, 41 percent of participants in the Eylea group received laser treatment to treat their macular edema, compared with 64 percent of participants in the Avastin group and 52 percent in the Lucentis group.\nThe risk of heart attack, stroke, or death from a cardiovascular condition or an unknown cause by end of the trial was higher among participants in the Lucentis group.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly spells out that the trial was funded by the National Eye Institute, part of the National Institutes of Health. It further states that two drug companies provided their drugs for the trial.", "answer": 1}, {"article": "About UABKnown for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama\u2019s largest employer and an internationally renowned research university and academic medical center; its professional schools and specialty patient-care programs are consistently ranked among the nation\u2019s top 50.\n\u201cIt is critical for eye care professionals to have a dialogue with patients who report symptoms because dry eye can be a progressive ocular surface disease.\u201d\n\nThe twice-daily eye drop solution of 5 percent lifitegrast ophthalmic solution is the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\nThere is hope for dry eye patients worldwide.\u201d\n\nDiagnosis of dry eye is identified by an eye care professional based on careful evaluation of signs and symptoms, including dryness, discomfort, vision changes and damage to the surface of the eye.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\n\u201cDry eye is a common complaint to eye care professionals, with millions of U.S. adults experiencing the symptoms of this often chronic disease,\u201d Nichols said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release acknowledges that the person quoted was doing work for Shire plc, the company that makes the product. The release was correct to include this funder as a potential conflict of interest. It would also have been good to note that study was conducted by by the UAB Center for Translational Research.", "answer": 1}, {"article": "In this study, after 12 months, it\u2019s a 9-in-10 chance.\u201d\n\nThe men in the study were aged 45 to 80 with medium- to high-risk cancer, and would likely have undergone surgery or radiotherapy down the line.\nProstate cancer is the most common cancer among men.\nFewer side effects would also lower other health care costs, he said.\nOverall, about 95% of the men were cancer-free after a full year following the trial.\nThe new study, designed as a proof-of-concept study, involved just 41 men.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were quoted \u2013 only the lead researcher.", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are cited in the story. Direct citations come from two sources \u2013 both of whom are researchers involved in the study. The story does bring up the fact that KEEPS was funded by the Kronos Longevity Research Institute, a nonprofit organization in Phoenix. No conflicts of interests are listed. But it\u2019s not clear who actually paid for this substantial study. A non-profit institute does not mean that it is free of pharmaceutical industry support.\u00a0The organization Kronos institiute is supported by the nonprofit \u201cAurora Foundation\u201d, which gave $34 million for this study according to Indiana University Philanthropy website. Who are they?", "answer": 0}, {"article": "Our research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nThe research was conducted when mice had developed memory problems.\nThey were divided in groups of 10.\nResearchers observed that memory loss was fully reversed to the levels seen in mice without Alzheimer\u2019s.\nFirst group was given mefenamic acid dose and the other group was given placebo for one month through a mini-pump implanted under the skin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There\u00a0are no\u00a0independent sources in the story.", "answer": 0}, {"article": "There are plenty of questions left, said Dr. Ashesh Mehta, director of epilepsy surgery at the North Shore-LIJ Comprehensive Epilepsy Care Center in Great Neck, N.Y.\n\n\"This study is an important first step,\" said Mehta, who was not involved in the research.\nIn this study, the implants revealed that most patients were suffering more seizures than they thought; one patient who reported 11 a month was actually having more than 100.\n\"The next step would be to implant these in a larger sample of patients.\nIt may be the people who fall in the middle -- who have disabling seizures at unpredictable intervals -- who would stand to benefit the most, he said.\nFor 11 of the 15 patients, the implants seemed capable of correctly predicting a high risk of seizure at least 65 percent of the time.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert source contributed important cautious perspectives.\u00a0 The fact that the study was funded by the device manufacturer and that several of the authoring researchers work for the company was disclosed.", "answer": 1}, {"article": "For more information about ColonaryConcepts, LLC, please visit http://www.\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\n\"The ECP approach allows patients to eat solid food bars and drink palatable low-volume beverages, a patient-friendly design that participants in the study clearly favored over conventional preps,\" comments Dr. Siegel.\n\"Approximately 40% of those who ought to have a colonoscopy avoid the procedure, and the top reason cited for their avoidance is the prep,\" said Dr. Rex.\n\"By making the preparation for the procedure easier, we believe ECP can lower patient resistance to colonoscopies, and thus can help attain these important public health goals.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The developer of this prep, ColonaryConcepts, LLC, is clearly identified in the news release, and a couple of other sources are also clearly linked to the company.\u00a0 However, one source, identified as the principal investigator for the study, is described in a conference abstract as a consultant for the company, but that was not made clear in the release.", "answer": 0}, {"article": "For more information about NIH and its programs, visit http://www.\nWhile study participants with the lower blood pressure goal appeared to have better cardiovascular outcomes overall, the researchers caution all other hypertension patients to talk to their doctor to determine whether this lower goal is best for their individual care.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nThe new analysis singles out adults aged 75 and older and confirms that those with high blood pressure also benefit from the lower pressure target similar to the larger group studied in the earlier research: non-diabetic adults aged 50 and older.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While this release does identify the main funding sources for the trial, it fails to mention any potential conflicts of interest, even though the paper itself discloses that three of the authors had numerous financial links to pharmaceutical firms.", "answer": 0}, {"article": "In March of this year, based upon earlier studies utilizing the test, Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, issued a draft local coverage determination (LCD) for the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nThis blinded four-year study followed 142 mCRPC patients who were treated at MSK, The Royal Marsden, or the London Health Sciences Centre.\nIt is estimated that 50,000 patients a year may be eligible for and benefit from the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nThe PROPHECY study investigated the AR-V7 test in patients receiving ARSi therapy and demonstrated that patients who tested positive had worse survival by all measures and had no clinical benefit from ARSi therapy.\nThe blood test called, Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 is commercially available in the U.S. through Epic Science's partnership with Genomic Health, Inc. (NASDAQ: GHDX).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that Epic Sciences \u201cdesigned\u201d the test and that different research institutions led research studies on the blood test. The release could have been much more transparent about who funded the research.\nThe study didn\u2019t mention all of the researchers\u2019 industry ties, but it did mention that some of the researchers are employed by Epic Sciences, the developer of the test.", "answer": 0}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\nCompared with oral medication, he says, \u201cthe odds of success are better with the laser; plus, there\u2019s no side effects.\u201d\n\nThe most common oral treatment, Lamisil, works for about two out of three patients, according to Lamisil\u2019s FDA-approved prescribing information, but it has been associated with rare cases of serious liver problems.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nIn one small study about laser treatment for toenail fungus, which appeared last year in the Journal of the American Podiatric Medical Association, \u201c26 eligible toes (ten mild, seven moderate, and nine severe)\u201d were treated with a laser produced by Nomir Medical Technologies, which is still seeking FDA approval.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are multiple sources quoted and some are critical of laser treatment, but, on balance we thought too much weight was given to a conflicted physician and a conflicted study. The physician who is quoted the most frequently is heavily selling these treatments. And the only study presented as proof of the laser treatment\u2019s efficacy is also the only study being promoted on the website of the company highlighted in the story, PinPointe USA. The author of that study is\u00a0the head of\u00a0PinPointe\u2019s Advisory Panel. http://pinpointefootlaser.com/news-and-events/press-releases/dr-adam-landsman-appointed-head-of-pinpointe-usas-advisory-panel\u00a0This should have been noted in the story.", "answer": 0}, {"article": "\u2022 If you have any question or request regarding interview opportunities, please contact:\n\u2022 For full details of a session, have a look at the Scientific Programme & Planner: http://spo.\nIts mission is to reduce the burden of cardiovascular disease in Europe.\nIn this meta-analysis a low dose of activity resulted in a mortality rate reduction of 22%.\nHowever, such a correlation between the level of physical activity and risk of death has not been so clearly determined in the elderly.\nRelation between physical activity and morbi-mortality of elderly people: the Proof cohort study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention any funding sources for the study or potential conflicts of interest.", "answer": 0}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not seek an outside perspective. The competing USA Today story quoted 3 other experts who provided valuable context.", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\nThe study's lead author, Dr. Paul M. Palevsky, said the results may lead to a large savings in U.S. health care costs, estimated at $100 million to $250 million a year for this type of patient.\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no evidence that the newspaper interviewed anyone for this story.\u00a0 The perspectives of the study\u2019s lead author and of the editorial writer both appear to be gleaned directly from the New England Journal of Medicine. \nThe story would have been improved by including comments from interviews with clinicians about what this information means to people who may need to deal with acute kidney injury in the future.\u00a0", "answer": 0}, {"article": "Rising levels of PSA (prostate-specific antigen) are a sign that prostate cancer may be getting worse.\nThe study is the latest to demonstrate pomegranate's promising antitumor effects, says study head Michael Carducci, MD, professor of oncology and urology at Johns Hopkins Medical Institutes.\n\"The results were similar regardless of whether the men took one capsule or three,\" Carducci tells WebMD.\nHowever, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nIn 2009, other researchers reported that pomegranate juice may also prevent prostate cancer from getting worse.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The input from the Sloan-Kettering expert saved the story.\nAnd the story did disclose that the lead author \u201cis an unpaid consultant to POM Wonderful, which makes both the pomegranate capsules and the juice used in the earlier study.\u201d", "answer": 1}, {"article": "D'Amico stressed that men should not start taking vitamin D supplements in hopes of slowing or curing prostate cancer.\n\"Vitamin D decreases inflammation in tissues, and inflammation is a driver of cancer,\" explained Bruce Hollis, the study's lead researcher and a professor of pediatrics, biochemistry and molecular biology at the Medical University of South Carolina in Charleston.\nFor the study, researchers randomly assigned 37 men who elected to have their prostate removed to receive either 4,000 international units (IU) of vitamin D or an inactive placebo daily for 60 days before their operation.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\nBut Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that this study was too small to reach any definitive conclusion about the value of vitamin D in fighting prostate cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes the chief of radiation oncology at Brigham and Women\u2019s Hospital in Boston in the strongest possible way concluding that the study was too small to establish any value of vitamin D supplements and prostate cancer prevention or therapy. There is no indication that the vitamin supplement industry had any role in the research. However, the article might have pointed out that the researcher, Bruce Hollis, has been conducting studies about the benefits of vitamin D for decades and is a widely quoted expert on the potential benefits of the vitamin in disease prevention. Hollis was quoted elsewhere on this study saying that \u201cdoctors should be recommending vitamin D\u2083 for men with low-grade prostate cancer,\u201d and we\u2019re glad to see that HealthDay did not pass along those overly enthusiastic comments.", "answer": 1}, {"article": "Eteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nIt would also represent a success, after decades of setbacks, for the technology eteplirsen uses, called antisense, which is a way of turning off specific genes.\nAlso, eteplirsen would be appropriate for only about 13 percent to 15 percent of Duchenne patients, those with the particular genetic mutation the drug is meant to counteract.\nOne possible reason for skepticism is that two of the boys on a lower dose of the drug rapidly lost the ability to walk, even though the level of dystrophin in their muscles increased substantially.\nIf eteplirsen gets to market, it would come nearly three decades after the 1986 discovery of the gene responsible for Duchenne.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is based on a pre-abstract release of information from the company.\u00a0 The study\u2019s principal investigator, the company CEO and parents of children enrolled in the study are the only sources quoted in the story.\u00a0 We think that an independent expert should have been quoted.", "answer": 0}, {"article": "People who had worse vision at the beginning of the study had worse scores on the cognitive exam as well.\nPoor eyesight and weakening mental function are common in older people and related to one another, but the question of whether vision influences cognition, or vice versa, has not been clear, the study team writes in JAMA Ophthalmology.\n(Reuters Health) - Waning eyesight may hasten the pace of cognitive decline in older people, suggests a U.S. study.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\nWhile mental function at one check-up was also related to vision at the following exam, the effect of vision on subsequent mental function was significantly stronger.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study was funded by the National Eye Institute and the Jane Kroger Fund. It would have been beneficial to include the funding sources in the story. However, omitting the name of a government or non-profit funder does not merit a Not Satisfactory rating.", "answer": 1}, {"article": "\u201cThe findings were exciting,\u201d she said.\nIn coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nAfter 12 weeks of daily yoga and coherent breathing, the subjects\u2019 depressive symptoms significantly decreased and their levels of gamma-aminobutyric acid, a brain chemical that has calming and anti-anxiety effects, had increased.\nIf you have never practiced breathing exercises before, you may have to work up to this practice slowly, starting with inhaling and exhaling to the count of three and working your way up to six.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is the biggest shortcoming of the article: All of those quoted have research and/or books to promote. The story could have used some sources who have a broader view of therapeutic approaches to stress.", "answer": 0}, {"article": "When she saw them, she said, \u201cI asked my analyst to rerun the data.\u201d\n\nNow, researchers say, the challenge is to find out why the test missed so many cancers, in particular, those on the right side of the colon, and whether the problem can be fixed.\nThat leaves several other possibilities.\nIt might be that Canadian doctors were not sufficiently skilled.\nAnd they should do a high volume of screening.\nThe tests are \u201chugely expensive,\u201d he said, and insurers may not pay for more frequent colonoscopies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "Over the 18-year period, the number of breast cancers diagnosed at very early stages increased 66 percent, while the number of more advanced cancers (stage 3) decreased by 66 percent.\nIn 2009, the U.S. Preventive Services Task Force issued mammogram recommendations.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\nThere was a decrease found in cancers being diagnosed at later stages in those whose cancers were found on mammograms.\nWhen considering its recommendation, the task force took all available evidence into account, including published studies, Moyer noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did interview the chair of the U.S. Preventive Services Task Force (USPSTF).", "answer": 1}, {"article": "The study had several limitations.\n\u201cUnless low-dose aspirin is taken continuously, there is little protection against colorectal cancer,\u201d Dr. Soren Friis from the Danish Cancer Society Research Center in Copenhagen told Reuters Health.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\n\u201cThe public should not take any medication regularly without consulting with a physician.\u201d\n\nDr. Gurpreet Singh Ranger from Upper River Valley Hospital, Waterville, New Brunswick and Dalhousie Medical School, in Halifax, Nova Scotia, Canada, agreed with Dr. Friis.\nFor instance, the researchers only had data for users who obtained their aspirin or NSAIDs from doctors\u2019 prescriptions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comment from Dr. Gurpreet Singh-Ranger, who apparently was not involved with the study, so we\u2019ll give it a pass. The story\u00a0would have been stronger had it told the reader what made him an authority on the topic.", "answer": 1}, {"article": "the bigger issue though is, is the increased costs associated with protons worth it to society?\nIt's the most expensive device in medicine today.\nAnd with no side effects.\n\"This is three stories.\nBut proton beam therapy is at the heart of the debate over rising health-care costs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "The Dana-Farber scientists say current [EGFR] inhibitors Iressa and Tarceva prevent EGFR from sending signals that are essential to keep tumor cells growing, the researchers say.\nThe scientists say in the news release that not only did they find that a compound called WZ4002 can slow tumor growth, but that it is possible to \"selectively target the drug-resistant mutant EGFR in tumors, with relatively less effect on the normal EGFR in health tissues.\"\nIt's early to discuss the use of such compounds in patients, the scientists say, but one of the researchers, Michael J. Eck, MD, PhD, also of Dana-Farber, says he's optimistic their approach \"will lead to an effective treatment for the thousands of non-small cell lung cancer patients worldwide who develop resistance to Iressa and Tarceva every year.\"\nThe scientists say non-small cell lung cancers that had become invulnerable to the chemotherapy drugs Iressa and Tarceva were stymied in a study by a compound designed and formulated in the Dana-Farber laboratory.\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source is cited besides the ACS statistics on lung cancer. Any story that allows a researcher to make bold claims such as that this research \"will lead to an effective treatment for the thousands of non-small cell lung cancer patients worldwide\" demands an independent perspective.\u00a0 ", "answer": 0}, {"article": "London, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\n\"With this type of vaccine, you would at least be able to start using the vaccine as soon as you knew a new pandemic was starting.\nYou could stockpile the vaccine and wouldn't have this wait to make a new pandemic-specific vaccine,\" she said.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nNormally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no quotations in the story, only reporting on what appeared in the journal Menopause.\u00a0 There are no comments from independent sources and also no mention of conflicts of interest.", "answer": 0}]